Biliary cirrhosis, NAS

CHIRBIL_NAS

primary biliary cirrhosis: Primary biliary cholangitis (PBC) is a chronic and slowly progressive cholestatic liver disease of autoimmune etiology characterized by injury of the intrahepatic bile ducts that may eventually lead to liver failure.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	519870
1. Apply sex-specific rule None	519870
2. Check conditions None	519870
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — K74.5 Cause of death: ICD-10 — K74.5 2 out of 7 registries used, show all original rules.	111
4. Check minimum number of events None	111
5. Include endpoints None	111
6. Filter based on genotype QC (FinnGen only)	105

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

First used in FinnGen datafreeze: DF2
Parent code in ICD-10: K74
Name in latin: Cirrhosis biliaris non specificata

NAME	CHIRBIL_NAS
CONTROL_EXCLUDE
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	K745
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	K745
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Biliary cirrhosis, NAS based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	740	440	291
Only index persons	591	365	226
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.01
Only index persons	0.01	0.01	0.01
Median age at first event (years)
Whole population	66.30	67.90	64.08
Only index persons	65.48	66.47	63.90

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	105	69	36
Unadjusted period prevalence (%)	0.02	0.02	0.02
Median age at first event (years)	65.28	64.72	66.36

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
111: Matched controls
1110

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

K74.5

ICD-10 Finland

Biliary cirrhosis, unspecified

+∞

160.1

111

A05AA02

ATC

ursodeoxycholic acid; oral

240.8

78.9

K74.3

ICD-10 Finland

Primary biliary cirrhosis

416.5

64.6

202

Kela drug reimbursment

Connective tissue diseases, rheumatoid arthritis and comparable disease

17.3

53.4

JJ2AT

NOMESCO Finland

Biopsy of liver with ultrasound guidance

82.3

41.5

JN1AE

NOMESCO Finland

Ultrasound examination of upper part of abdomen

10.3

29.5

K74.6

ICD-10 Finland

Other and unspecified cirrhosis of liver

45.6

29.0

JN3AE

NOMESCO Finland

Abdominal ultrasound examination

7.9

24.1

I85.9

ICD-10 Finland

Oesophageal varices without bleeding

50.3

20.5

UJD10

NOMESCO Finland

Esophagoscopy, gastroscopy and duodenoscopy

6.2

20.2

262

C03DA01

ATC

spironolactone; oral

5.5

15.6

103

JJ1LE

NOMESCO Finland

Ultrasound elastography of liver

53.1

15.6

JA3AT

NOMESCO Finland

Cathetrisation of abdominal cavity with ultrasound guidance

85.6

13.9

R18

ICD-10 Finland

Ascites

22.6

13.5

NK6QA

NOMESCO Finland

Measurement of bone density from two or more locations with X-ray

5.6

11.4

K76.9

ICD-10 Finland

Liver disease, unspecified

31.7

11.0

K73.2

ICD-10 Finland

Chronic active hepatitis, not elsewhere classified

121.0

10.6

C03CA01

ATC

furosemide; systemic

3.6

10.1

320

L04AX01

ATC

azathioprine; systemic

13.1

10.0

A07EA06

ATC

budesonide; oral, local oral

11.7

10.0

I85.0

ICD-10 Finland

Oesophageal varices with bleeding

60.4

9.8

JN1DG

NOMESCO Finland

Very extensive MRI examination of upper part of abdomen with high intensity magnet

15.8

9.0

TJJ00

NOMESCO Finland

Percutaneous needle biopsy of liver

97.1

8.5

K75.4

ICD-10 Finland

Autoimmune hepatitis

+∞

8.4

JCA22

NOMESCO Finland

Endoscopic ligature of oesophageal varices

36.3

8.2

D64.9

ICD-10 Finland

Anaemia, unspecified

3.8

8.0

K73.9

ICD-10 Finland

Chronic hepatitis, unspecified

48.5

7.8

JN1CG

NOMESCO Finland

Extensive MRI examination of upper part of abdomen with high intensity magnet

13.2

7.8

ZX120

NOMESCO Finland

Intravenous

3.9

7.7

K74.0

ICD-10 Finland

Hepatic fibrosis

85.6

7.5

D97

ICPC

Liver disease NOS

85.6

7.5

L04AA06

ATC

mycophenolic acid; systemic

17.2

7.4

M05BA04

ATC

alendronic acid; oral

3.9

7.4

C22.0

ICD-10 Finland

Malignant neoplasm: Liver cell carcinoma

32.3

7.3

K70.3

ICD-10 Finland

Alcoholic cirrhosis of liver

32.3

7.3

UJF32

NOMESCO Finland

Coloscopy

3.0

7.2

226

K83.0

ICD-10 Finland

Cholangitis

18.1

6.9

M34.1

ICD-10 Finland

CR(E)ST syndrome

42.7

6.8

L04AD02

ATC

tacrolimus; systemic

24.2

6.8

K92.1

ICD-10 Finland

Melaena

4.6

6.6

K75.9

ICD-10 Finland

Inflammatory liver disease, unspecified

19.4

6.4

JJC00

NOMESCO Finland

Allogenic transplantation of liver

28.5

6.3

A06AD11

ATC

lactulose; oral

3.2

6.3

121

5716A

ICD-9 Finland

Chronic liver disease and cirrhosis, Biliary cirrhosis[CIRRHOSIS BILIARIS PRIMARIA]

+∞

6.3

A07AA11

ATC

rifaximin; oral

+∞

6.3

TPH04

NOMESCO Finland

Cathetrisation of vein

2.9

6.3

167

C10AC01

ATC

colestyramine; oral

10.9

6.2

127

Kela drug reimbursment

Transplant complication

16.1

6.0

TimeCodeWAS

↥

TODO / Current known limitations:

Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
Legend / how to read the glyphs.
Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
Download CSV.
No filters and sorters.
Limited amount of endpoints (~400) having TimeCodeWAS data.
Cross-links to Risteys lab test pages for lab test codes.

OMOP concept

ln(OR)

%cases with code / %controls with code

2×2 table

Pharmacy visit
OMOP4822462 [581458]

1.0e+50

8.5e-01

—

1.4e+00

2.6e+00

1.0e+50

cases:100.00%

controls:95.77%

cases:100.00%

controls:88.29%

cases:72.07%

controls:52.52%

—

cases:80.56%

controls:51.58%

cases:98.99%

controls:87.62%

cases:100.00%

controls:95.29%

111

1063

111

980

130

583

527

—

572

537

941

133

869

Outpatient Visit
OP [9202]

9.4e-01

1.9e+00

1.1e+00

4.8e+00

1.4e+00

2.2e+00

1.7e+00

cases:88.29%

controls:74.59%

cases:87.39%

controls:50.45%

cases:27.93%

controls:11.26%

cases:45.95%

controls:0.72%

cases:32.41%

controls:10.73%

cases:89.90%

controls:50.37%

cases:95.29%

controls:78.29%

828

282

560

550

125

985

1102

119

990

541

533

714

198

Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]

9.7e-01

1.9e+00

3.3e+00

1.0e+50

2.8e+00

2.3e+00

1.7e+00

cases:18.02%

controls:7.66%

cases:20.72%

controls:3.69%

cases:16.22%

controls:0.72%

cases:4.50%

controls:0.00%

cases:9.26%

controls:0.63%

cases:30.30%

controls:4.19%

cases:45.88%

controls:13.60%

1025

1069

1102

106

1110

1102

1029

124

788

Gastroenterology
10 [38004455]

2.0e+00

3.1e+00

—

1.0e+50

—

4.0e+00

3.5e+00

cases:25.23%

controls:4.41%

cases:31.53%

controls:2.07%

—

cases:32.43%

controls:0.00%

—

cases:50.51%

controls:1.86%

cases:64.71%

controls:5.15%

1061

1087

—

1110

—

1054

865

Internal Medicine
11 [38004456]

1.3e+00

1.9e+00

2.1e+00

—

2.5e+00

2.2e+00

2.0e+00

cases:54.95%

controls:24.05%

cases:44.14%

controls:10.54%

cases:15.32%

controls:2.07%

—

cases:14.81%

controls:1.35%

cases:48.48%

controls:9.31%

cases:68.24%

controls:22.92%

267

843

117

993

1087

—

1094

100

974

209

703

Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]

1.5e+00

3.1e+00

—

2.6e+00

2.5e+00

cases:16.22%

controls:4.14%

cases:13.51%

controls:0.72%

—

cases:17.17%

controls:1.58%

cases:32.94%

controls:4.06%

1064

1102

—

1057

875

INR in Blood by Coagulation assay
34714-6 [3032080]

4.9e-01

1.8e+00

2.5e+00

1.0e+50

2.1e+00

1.5e+00

1.4e+00

cases:13.51%

controls:8.74%

cases:18.92%

controls:3.87%

cases:15.32%

controls:1.44%

cases:5.41%

controls:0.00%

cases:10.19%

controls:1.35%

cases:20.20%

controls:5.21%

cases:36.47%

controls:12.50%

1013

1067

1094

105

1110

1094

1018

114

798

Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]

3.6e-01

1.4e+00

2.8e+00

—

2.2e+00

1.7e+00

1.1e+00

cases:19.82%

controls:14.68%

cases:29.73%

controls:9.10%

cases:20.72%

controls:1.53%

—

cases:12.04%

controls:1.44%

cases:37.37%

controls:9.87%

cases:48.24%

controls:23.79%

163

947

101

1009

1093

—

1093

106

968

217

695

Upper gastrointestinal surgery
106 [44777669]

8.0e-01

2.5e+00

—

1.0e+50

2.9e+00

1.5e+00

1.9e+00

cases:18.92%

controls:9.46%

cases:23.42%

controls:2.34%

—

cases:9.91%

controls:0.00%

cases:10.19%

controls:0.63%

cases:12.12%

controls:2.89%

cases:42.35%

controls:9.65%

105

1005

1084

—

100

1110

1102

1043

824

Outpatient Hospital
22 [8756]

3.9e-01

1.3e+00

2.8e+00

1.0e+50

1.7e+00

1.5e+00

1.3e+00

cases:35.14%

controls:26.76%

cases:22.52%

controls:7.39%

cases:9.91%

controls:0.63%

cases:16.22%

controls:0.00%

cases:8.33%

controls:1.62%

cases:29.29%

controls:8.66%

cases:56.47%

controls:25.44%

297

813

1028

100

1103

1110

1091

981

232

680

spironolactone; oral
C03DA01 [21601534]

1.3e+00

1.7e+00

—

2.3e+00

2.2e+00

2.4e+00

cases:9.01%

controls:2.61%

cases:9.01%

controls:1.71%

—

cases:6.48%

controls:0.72%

cases:17.17%

controls:2.14%

cases:20.00%

controls:2.30%

101

1081

101

1091

—

101

1101

1051

891

Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]

1.1e+00

2.2e+00

2.9e+00

—

1.6e+00

1.5e+00

cases:10.81%

controls:4.05%

cases:13.51%

controls:1.62%

cases:9.01%

controls:0.54%

—

cases:12.12%

controls:2.61%

cases:28.24%

controls:8.44%

1065

1092

101

1104

—

1046

835

Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]

7.0e-01

1.6e+00

—

2.5e+00

2.1e+00

1.9e+00

cases:13.51%

controls:7.21%

cases:14.41%

controls:3.24%

—

cases:7.41%

controls:0.63%

cases:25.25%

controls:3.91%

cases:41.18%

controls:9.10%

1030

1074

—

100

1102

1032

829

pantoprazole; oral, parenteral
A02BC02 [21600097]

6.3e-01

1.6e+00

1.7e+00

—

1.9e+00

1.3e+00

1.2e+00

cases:25.23%

controls:15.23%

cases:28.83%

controls:7.66%

cases:9.01%

controls:1.80%

—

cases:11.11%

controls:1.89%

cases:26.26%

controls:8.66%

cases:45.88%

controls:20.07%

169

941

1025

101

1090

—

1088

981

183

729

Inpatient Hospital
21 [8717]

4.6e-01

1.2e+00

2.2e+00

—

1.7e+00

1.4e+00

1.2e+00

cases:45.05%

controls:34.05%

cases:28.83%

controls:11.17%

cases:10.81%

controls:1.35%

—

cases:12.04%

controls:2.52%

cases:37.37%

controls:12.48%

cases:60.00%

controls:30.48%

378

732

124

986

1095

—

1081

134

940

278

634

Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]

6.3e-01

1.7e+00

—

2.2e+00

1.9e+00

1.3e+00

cases:16.22%

controls:9.37%

cases:17.12%

controls:3.69%

—

cases:5.56%

controls:0.63%

cases:22.22%

controls:4.28%

cases:38.82%

controls:14.91%

104

1006

1069

—

102

1102

1028

136

776

Emergency Room Visit
ER [9203]

7.0e-01

1.4e+00

2.0e+00

1.0e+50

1.3e+00

1.2e+00

cases:49.55%

controls:32.70%

cases:34.23%

controls:11.44%

cases:10.81%

controls:1.62%

cases:14.41%

controls:0.00%

cases:5.56%

controls:1.53%

cases:33.33%

controls:12.94%

cases:63.53%

controls:33.55%

363

747

127

983

1092

1110

102

1092

139

935

306

606

General Surgery
2 [38004447]

3.6e-01

1.3e+00

1.9e+00

1.0e+50

2.3e+00

1.7e+00

1.0e+00

cases:27.03%

controls:20.54%

cases:19.82%

controls:6.40%

cases:4.50%

controls:0.72%

cases:8.11%

controls:0.00%

cases:6.48%

controls:0.72%

cases:22.22%

controls:4.75%

cases:35.29%

controls:16.56%

228

882

1039

106

1102

102

1110

101

1101

1023

151

761

Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]

—

1.0e+50

—

3.0e+00

3.1e+00

—

cases:5.41%

controls:0.00%

—

cases:10.10%

controls:0.56%

cases:22.35%

controls:1.32%

—

105

1110

—

1068

900

25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]

4.7e-01

3.4e-01

3.0e+00

—

-1.0e+50

1.4e+00

1.2e+00

cases:11.71%

controls:7.66%

cases:4.50%

controls:3.24%

cases:8.11%

controls:0.45%

—

cases:0.00%

controls:0.45%

cases:16.16%

controls:4.38%

cases:24.71%

controls:9.32%

1025

106

1074

102

1105

—

108

1104

1027

827

C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]

7.1e-02

7.5e-01

2.2e+00

—

1.6e+00

9.1e-01

7.9e-01

cases:21.62%

controls:20.45%

cases:25.23%

controls:13.78%

cases:18.02%

controls:2.43%

—

cases:9.26%

controls:1.98%

cases:32.32%

controls:16.11%

cases:54.12%

controls:34.76%

227

883

153

957

1083

—

1087

173

901

317

595

Prothrombin time (PT) actual/Normal
5894-1 [3033658]

1.1e+00

2.0e+00

—

1.8e+00

1.6e+00

cases:9.01%

controls:3.33%

cases:7.21%

controls:0.99%

—

cases:11.11%

controls:1.96%

cases:21.18%

controls:5.15%

101

1073

103

1099

—

1053

865

Laboratory Visit
OMOP4822461 [32036]

-8.1e-02

2.9e-01

1.4e+00

2.9e+00

9.7e-01

4.0e-01

1.3e-01

cases:27.03%

controls:28.65%

cases:35.14%

controls:28.83%

cases:29.73%

controls:9.10%

cases:10.81%

controls:0.63%

cases:17.59%

controls:7.48%

cases:41.41%

controls:32.22%

cases:55.29%

controls:51.97%

318

792

320

790

101

1009

1103

1026

346

728

474

438

Thorax X-ray examination
GD1AA [2001303617]

8.0e-01

2.0e+00

—

1.7e+00

1.5e+00

cases:16.22%

controls:8.02%

cases:13.51%

controls:2.16%

—

cases:15.15%

controls:3.26%

cases:32.94%

controls:9.98%

1021

1086

—

1039

821

Connective tissue diseases, rheumatoid arthritis and comparable disease
202 [2001600200]

2.7e+00

—

2.3e+00

cases:9.91%

controls:0.72%

—

cases:11.76%

controls:1.32%

100

1102

—

900

aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]

1.3e+00

2.5e+00

—

2.2e+00

1.1e+00

cases:6.31%

controls:1.80%

cases:6.31%

controls:0.54%

—

cases:7.07%

controls:0.84%

cases:9.41%

controls:3.29%

104

1090

104

1104

—

1065

882

Ultrasound examination of upper part of abdomen
JN1AE [2001305517]

2.2e+00

—

2.5e+00

cases:5.41%

controls:0.63%

—

cases:17.65%

controls:1.75%

105

1103

—

896

Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]

-1.3e-01

7.2e-01

2.0e+00

1.0e+50

1.8e+00

7.8e-01

3.3e-01

cases:23.42%

controls:25.77%

cases:32.43%

controls:18.92%

cases:21.62%

controls:3.69%

cases:5.41%

controls:0.00%

cases:12.96%

controls:2.43%

cases:38.38%

controls:22.16%

cases:51.76%

controls:43.53%

286

824

210

900

1069

105

1110

1082

238

836

397

515

Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]

2.6e-01

7.3e-01

2.5e+00

—

1.1e+00

8.9e-01

cases:17.12%

controls:13.69%

cases:12.61%

controls:6.49%

cases:10.81%

controls:0.99%

—

cases:19.19%

controls:7.17%

cases:38.82%

controls:20.72%

152

958

1038

1099

—

997

189

723

Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]

4.1e-01

4.2e-01

2.1e+00

—

1.4e+00

9.3e-01

cases:12.61%

controls:8.74%

cases:7.21%

controls:4.86%

cases:5.41%

controls:0.72%

—

cases:15.15%

controls:4.38%

cases:25.88%

controls:12.06%

1013

103

1056

105

1102

—

1027

110

802

IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]

1.1e+00

2.5e+00

—

1.8e+00

cases:4.50%

controls:1.53%

cases:8.11%

controls:0.72%

—

cases:5.05%

controls:0.84%

cases:8.24%

controls:1.43%

106

1093

102

1102

—

1065

899

calcium (different salts in combination); oral
A12AA20 [21600872]

7.3e-01

1.1e+00

6.2e-01

—

1.3e+00

1.8e+00

cases:21.62%

controls:11.71%

cases:23.42%

controls:9.01%

cases:5.41%

controls:2.97%

—

cases:8.33%

controls:2.43%

cases:30.30%

controls:10.24%

cases:51.76%

controls:15.24%

130

980

100

1010

105

1077

—

1082

110

964

139

773

Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]

-2.1e-01

1.6e+00

—

1.0e+50

—

1.5e+00

1.1e+00

cases:5.41%

controls:6.58%

cases:8.11%

controls:1.71%

—

cases:5.41%

controls:0.00%

—

cases:10.10%

controls:2.51%

cases:23.53%

controls:9.21%

105

1037

102

1091

—

105

1110

—

1047

828

Eosinophils [#/volume] in Blood
26449-9 [3013115]

3.1e-01

6.3e-01

1.7e+00

—

1.3e+00

9.7e-01

cases:10.81%

controls:8.20%

cases:8.11%

controls:4.50%

cases:7.21%

controls:1.35%

—

cases:15.15%

controls:4.47%

cases:27.06%

controls:12.28%

1019

102

1060

103

1095

—

1026

112

800

Other and unspecified abdominal pain
R10.4 [45568113]

6.8e-01

2.6e+00

—

1.7e+00

1.3e+00

cases:9.01%

controls:4.77%

cases:11.71%

controls:0.99%

—

cases:5.05%

controls:0.93%

cases:15.29%

controls:4.61%

101

1057

1099

—

1064

870

propranolol; oral, parenteral
C07AA05 [21601670]

6.8e-01

1.7e+00

—

2.0e+00

1.9e+00

cases:4.50%

controls:2.34%

cases:6.31%

controls:1.17%

—

cases:10.10%

controls:1.49%

cases:15.29%

controls:2.74%

106

1084

104

1097

—

1058

887

Coloscopy
UJF32 [2001305029]

1.0e+00

2.1e+00

—

1.7e+00

cases:10.81%

controls:4.14%

cases:9.01%

controls:1.17%

—

cases:21.18%

controls:4.71%

1064

101

1097

—

869

Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]

2.4e-01

5.4e-01

2.0e+00

—

1.7e+00

7.1e-01

2.4e-01

cases:20.72%

controls:17.03%

cases:23.42%

controls:15.14%

cases:18.92%

controls:2.97%

—

cases:12.96%

controls:2.71%

cases:26.26%

controls:14.90%

cases:34.12%

controls:28.95%

189

921

168

942

1077

—

1079

160

914

264

648

Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]

9.4e-03

7.5e-01

2.5e+00

—

7.8e-01

9.4e-01

cases:10.81%

controls:10.72%

cases:9.91%

controls:4.95%

cases:5.41%

controls:0.45%

—

cases:11.11%

controls:5.40%

cases:30.59%

controls:14.69%

119

991

100

1055

105

1105

—

1016

134

778

Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]

7.2e-01

2.0e+00

—

1.5e+00

1.4e+00

cases:9.01%

controls:4.59%

cases:9.01%

controls:1.26%

—

cases:8.08%

controls:1.86%

cases:23.53%

controls:6.91%

101

1059

101

1096

—

1054

849

tramadol; oral, parenteral, rectal
N02AX02 [21604298]

5.6e-01

9.9e-01

—

2.1e+00

1.4e+00

cases:13.51%

controls:8.20%

cases:7.21%

controls:2.79%

—

cases:13.13%

controls:1.86%

cases:20.00%

controls:6.03%

1019

103

1079

—

1054

857

Type 2 diabetes mellitus, without complications
E11.9 [45561952]

1.2e+00

9.6e-01

2.0e+00

—

2.2e+00

1.1e+00

3.4e-01

cases:18.92%

controls:6.58%

cases:9.91%

controls:4.05%

cases:4.50%

controls:0.63%

—

cases:5.56%

controls:0.63%

cases:12.12%

controls:4.56%

cases:11.76%

controls:8.66%

1037

100

1065

106

1103

—

102

1102

1025

833

CBC panel - Blood by Automated count
58410-2 [40761511]

-5.2e-02

5.1e-01

1.8e+00

—

1.5e+00

6.7e-01

2.5e-01

cases:21.62%

controls:22.52%

cases:24.32%

controls:16.22%

cases:13.51%

controls:2.43%

—

cases:10.19%

controls:2.43%

cases:29.29%

controls:17.50%

cases:44.71%

controls:38.60%

250

860

180

930

1083

—

1082

188

886

352

560

Basophils [#/volume] in Blood
26444-0 [3006315]

3.7e-01

6.9e-01

1.9e+00

—

1.4e+00

8.9e-01

cases:10.81%

controls:7.75%

cases:8.11%

controls:4.23%

cases:7.21%

controls:1.17%

—

cases:15.15%

controls:4.19%

cases:24.71%

controls:11.84%

1024

102

1063

103

1097

—

1029

108

804

Monocytes [#/volume] in Blood
26484-6 [3001604]

3.8e-01

7.1e-01

1.9e+00

—

1.4e+00

9.0e-01

cases:10.81%

controls:7.66%

cases:8.11%

controls:4.14%

cases:7.21%

controls:1.17%

—

cases:15.15%

controls:4.19%

cases:24.71%

controls:11.73%

1025

102

1064

103

1097

—

1029

107

805

Supplier / Service Provider
OMOP5117446 [33004]

-6.7e-01

—

-1.0e+50

—

2.1e+00

3.2e+00

cases:11.71%

controls:20.63%

—

cases:0.00%

controls:0.72%

—

cases:5.05%

controls:0.65%

cases:23.53%

controls:1.21%

229

881

—

111

1102

—

1067

901

Platelets [#/volume] in Blood
26515-7 [3007461]

-6.0e-02

3.7e-01

1.8e+00

—

1.3e+00

5.9e-01

2.9e-01

cases:26.13%

controls:27.30%

cases:32.43%

controls:24.86%

cases:25.23%

controls:5.05%

—

cases:14.81%

controls:4.33%

cases:39.39%

controls:26.54%

cases:54.12%

controls:46.93%

303

807

276

834

1054

—

1061

285

789

428

484

Lymphocytes [#/volume] in Blood
26474-7 [3019198]

2.5e-01

6.0e-01

1.9e+00

—

1.3e+00

8.2e-01

cases:10.81%

controls:8.65%

cases:8.11%

controls:4.59%

cases:7.21%

controls:1.17%

—

cases:15.15%

controls:4.66%

cases:24.71%

controls:12.61%

1014

102

1059

103

1097

—

1024

115

797

MCH [Entitic mass]
28539-5 [3035941]

-6.4e-02

3.7e-01

1.8e+00

—

1.3e+00

5.7e-01

2.7e-01

cases:26.13%

controls:27.39%

cases:32.43%

controls:24.95%

cases:25.23%

controls:5.05%

—

cases:14.81%

controls:4.51%

cases:39.39%

controls:26.91%

cases:54.12%

controls:47.26%

304

806

277

833

1054

—

1059

289

785

431

481

Hemoglobin [Mass/volume] in Blood
718-7 [3000963]

-7.3e-02

3.6e-01

1.8e+00

—

1.3e+00

5.7e-01

2.7e-01

cases:26.13%

controls:27.57%

cases:32.43%

controls:25.14%

cases:25.23%

controls:5.05%

—

cases:14.81%

controls:4.51%

cases:39.39%

controls:26.91%

cases:54.12%

controls:47.37%

306

804

279

831

1054

—

1059

289

785

432

480

Leukocytes [#/volume] in Blood
26464-8 [3010813]

-6.9e-02

3.6e-01

1.8e+00

—

1.3e+00

5.7e-01

2.8e-01

cases:26.13%

controls:27.48%

cases:32.43%

controls:25.05%

cases:25.23%

controls:5.05%

—

cases:14.81%

controls:4.51%

cases:39.39%

controls:26.82%

cases:54.12%

controls:47.15%

305

805

278

832

1054

—

1059

288

786

430

482

Erythrocytes [#/volume] in Blood
26453-1 [3026361]

-6.9e-02

3.6e-01

1.8e+00

—

1.3e+00

5.7e-01

2.7e-01

cases:26.13%

controls:27.48%

cases:32.43%

controls:25.14%

cases:25.23%

controls:5.05%

—

cases:14.81%

controls:4.51%

cases:39.39%

controls:26.91%

cases:54.12%

controls:47.26%

305

805

279

831

1054

—

1059

289

785

431

481

MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]

-6.9e-02

3.6e-01

1.8e+00

—

1.3e+00

5.7e-01

2.7e-01

cases:26.13%

controls:27.48%

cases:32.43%

controls:25.14%

cases:25.23%

controls:5.05%

—

cases:14.81%

controls:4.51%

cases:39.39%

controls:26.91%

cases:54.12%

controls:47.26%

305

805

279

831

1054

—

1059

289

785

431

481

Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]

-6.9e-02

3.6e-01

1.8e+00

—

1.3e+00

5.7e-01

2.7e-01

cases:26.13%

controls:27.48%

cases:32.43%

controls:25.14%

cases:25.23%

controls:5.14%

—

cases:14.81%

controls:4.51%

cases:39.39%

controls:26.91%

cases:54.12%

controls:47.26%

305

805

279

831

1053

—

1059

289

785

431

481

Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]

2.5e-01

8.1e-01

1.9e+00

—

1.9e+00

1.1e+00

7.3e-01

cases:10.81%

controls:8.65%

cases:10.81%

controls:5.14%

cases:8.11%

controls:1.26%

—

cases:5.56%

controls:0.90%

cases:15.15%

controls:5.68%

cases:25.88%

controls:14.36%

1014

1053

102

1096

—

102

1099

1013

131

781

Blood type and Crossmatch panel - Blood
34531-4 [3044640]

6.6e-01

1.3e+00

—

1.8e+00

1.2e+00

cases:7.21%

controls:3.87%

cases:4.50%

controls:1.26%

—

cases:8.08%

controls:1.40%

cases:21.18%

controls:7.57%

103

1067

106

1096

—

1059

843

insulin glargine; parenteral
A10AE04 [21600739]

1.1e+00

1.6e+00

2.2e+00

—

1.4e+00

1.1e+00

cases:8.11%

controls:2.79%

cases:9.91%

controls:2.25%

cases:4.50%

controls:0.54%

—

cases:10.10%

controls:2.61%

cases:11.76%

controls:4.28%

102

1079

100

1085

106

1104

—

1046

873

insulin (beef); parenteral
A10AD02 [21600730]

1.1e+00

1.6e+00

2.2e+00

—

1.4e+00

1.1e+00

cases:8.11%

controls:2.79%

cases:9.91%

controls:2.25%

cases:4.50%

controls:0.54%

—

cases:10.10%

controls:2.61%

cases:11.76%

controls:4.28%

102

1079

100

1085

106

1104

—

1046

873

Scheduled procedure
ZXD10 [2001311387]

8.4e-01

1.1e+00

—

1.7e+00

1.3e+00

cases:12.61%

controls:5.86%

cases:5.41%

controls:1.89%

—

cases:9.09%

controls:1.77%

cases:20.00%

controls:6.58%

1045

105

1089

—

1055

852

Normoblasts [#/volume] in Blood
715-3 [3021589]

6.2e-01

6.5e-01

1.7e+00

—

1.8e+00

1.2e+00

9.1e-01

cases:12.61%

controls:7.21%

cases:10.81%

controls:5.95%

cases:8.11%

controls:1.53%

—

cases:6.48%

controls:1.17%

cases:15.15%

controls:5.03%

cases:18.82%

controls:8.55%

1030

1044

102

1093

—

101

1096

1020

834

Medical doctor
Z2221 [2001311556]

5.3e-01

1.3e+00

—

1.6e+00

1.3e+00

cases:8.11%

controls:4.95%

cases:8.11%

controls:2.25%

—

cases:9.09%

controls:1.96%

cases:16.47%

controls:5.04%

102

1055

102

1085

—

1053

866

Case Management Agency
251B00000X [38004193]

2.7e-01

1.2e-01

5.6e-01

2.8e+00

6.1e-01

3.7e-01

8.6e-01

cases:63.96%

controls:57.48%

cases:54.95%

controls:52.07%

cases:31.53%

controls:20.90%

cases:19.82%

controls:1.44%

cases:32.41%

controls:20.74%

cases:63.64%

controls:54.75%

cases:88.24%

controls:76.10%

638

472

578

532

232

878

1094

230

879

588

486

694

218

Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]

—

2.8e+00

—

cases:12.94%

controls:0.88%

—

904

Infectious Disease
44 [38004484]

—

2.7e+00

—

cases:9.41%

controls:0.66%

—

906

sulfamethoxazole and trimethoprim
J01EE01 [21602961]

-1.0e+50

—

2.7e+00

cases:0.00%

controls:0.54%

—

cases:9.41%

controls:0.66%

111

1104

—

906

One hour or less
ZXE00 [2001311394]

1.1e+00

8.9e-01

—

1.4e+00

1.6e+00

cases:17.12%

controls:6.31%

cases:4.50%

controls:1.89%

—

cases:6.06%

controls:1.58%

cases:23.53%

controls:5.92%

1040

106

1089

—

1057

858

IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]

—

1.0e+50

—

2.7e+00

—

cases:4.63%

controls:0.00%

—

cases:14.12%

controls:1.10%

—

103

1109

—

902

furosemide; oral, parenteral
C03CA01 [21601518]

4.7e-01

8.5e-01

—

1.3e+00

1.4e+00

cases:11.71%

controls:7.66%

cases:15.32%

controls:7.21%

—

cases:8.33%

controls:2.34%

cases:23.23%

controls:7.54%

cases:31.76%

controls:10.75%

1025

1030

—

1083

993

814

azathioprine; oral, parenteral
L04AX01 [21603927]

—

2.6e+00

—

cases:7.06%

controls:0.55%

—

907

Ammonium ion [Moles/volume] in Plasma
1845-7 [3023183]

—

2.6e+00

—

cases:8.24%

controls:0.66%

—

906

Abdominal ultrasound examination
JN3AE [2001305555]

1.6e+00

—

1.8e+00

2.6e+00

cases:7.21%

controls:1.53%

—

cases:6.06%

controls:1.02%

cases:21.18%

controls:1.97%

103

1093

—

1063

894

Basophils/Leukocytes in Blood
30180-4 [3022096]

2.2e-01

7.8e-01

1.6e+00

—

1.5e+00

1.0e+00

cases:9.01%

controls:7.39%

cases:8.11%

controls:3.87%

cases:5.41%

controls:1.17%

—

cases:15.15%

controls:3.91%

cases:25.88%

controls:10.96%

101

1028

102

1067

105

1097

—

1032

100

812

Monocytes/Leukocytes in Blood
26485-3 [3019069]

2.2e-01

7.8e-01

1.6e+00

—

1.4e+00

1.0e+00

cases:9.01%

controls:7.39%

cases:8.11%

controls:3.87%

cases:5.41%

controls:1.17%

—

cases:15.15%

controls:4.10%

cases:25.88%

controls:10.96%

101

1028

102

1067

105

1097

—

1030

100

812

Eosinophils/Leukocytes in Blood
26450-7 [3006504]

2.0e-01

7.8e-01

1.6e+00

—

1.4e+00

1.0e+00

cases:9.01%

controls:7.48%

cases:8.11%

controls:3.87%

cases:5.41%

controls:1.17%

—

cases:15.15%

controls:4.10%

cases:25.88%

controls:11.07%

101

1027

102

1067

105

1097

—

1030

101

811

Unstable angina
I20.09 [2000502389]

—

2.4e+00

—

cases:5.88%

controls:0.55%

—

907

Biopsy of liver with ultrasound guidance
JJ2AT [2001305254]

—

1.0e+50

—

1.0e+50

2.4e+00

—

cases:4.50%

controls:0.00%

—

cases:7.07%

controls:0.00%

cases:5.88%

controls:0.55%

—

106

1110

—

1074

907

Type 2 diabetes mellitus, with unspecified complications
E11.8 [45561951]

1.5e+00

2.4e+00

—

1.2e+00

cases:7.21%

controls:1.62%

cases:7.21%

controls:0.72%

—

cases:8.24%

controls:2.74%

103

1092

103

1102

—

887

Stomach Pathology biopsy report
66114-0 [40768797]

—

2.4e+00

—

1.5e+00

—

cases:6.31%

controls:0.63%

—

cases:8.24%

controls:1.97%

—

104

1103

—

894

Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]

4.7e-01

1.2e+00

2.4e+00

—

8.4e-01

7.7e-01

cases:8.11%

controls:5.23%

cases:9.91%

controls:3.06%

cases:6.31%

controls:0.63%

—

cases:7.07%

controls:3.17%

cases:17.65%

controls:8.99%

102

1052

100

1076

104

1103

—

1040

830

Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]

—

2.3e+00

—

1.4e+00

—

cases:4.50%

controls:0.45%

—

cases:5.88%

controls:1.54%

—

106

1105

—

898

Gastro-oesophageal reflux disease with oesophagitis
K21.0 [45543296]

—

2.3e+00

—

cases:4.50%

controls:0.45%

—

106

1105

—

IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]

—

1.0e+50

—

2.3e+00

—

cases:4.63%

controls:0.00%

—

cases:11.76%

controls:1.32%

—

103

1109

—

900

carvedilol; oral
C07AG02 [21601700]

—

2.0e+00

—

2.3e+00

2.0e+00

—

cases:4.50%

controls:0.63%

—

cases:6.06%

controls:0.65%

cases:5.88%

controls:0.88%

—

106

1103

—

1067

904

Neutrophils/Leukocytes in Blood
26511-6 [3018010]

1.4e-01

6.1e-01

1.6e+00

—

1.2e+00

9.6e-01

cases:9.01%

controls:7.93%

cases:7.21%

controls:4.05%

cases:5.41%

controls:1.17%

—

cases:14.14%

controls:4.56%

cases:24.71%

controls:11.18%

101

1022

103

1065

105

1097

—

1025

102

810

Type 2 diabetes mellitus, with ophthalmic complications
E11.3 [45591028]

2.2e+00

—

cases:5.41%

controls:0.63%

—

105

1103

—

Hematology
82 [38004501]

—

1.7e+00

—

2.1e+00

1.5e+00

—

cases:4.50%

controls:0.81%

—

cases:8.08%

controls:1.02%

cases:7.06%

controls:1.64%

—

106

1101

—

1063

897

X-ray examination of the lungs in one projection
GD1PA [2001303645]

-1.0e+50

—

2.1e+00

cases:0.00%

controls:0.54%

—

cases:10.59%

controls:1.43%

111

1104

—

899

Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]

—

2.0e+00

—

cases:8.24%

controls:1.21%

—

901

FEV1
20150-9 [3024653]

—

2.0e+00

—

cases:8.24%

controls:1.21%

—

901

FEV1/FVC
19926-5 [3011505]

—

2.0e+00

—

cases:8.24%

controls:1.21%

—

901

Pain localized to upper abdomen
R10.1 [45568111]

2.0e+00

—

1.1e+00

cases:7.21%

controls:1.08%

—

cases:7.06%

controls:2.52%

103

1098

—

889

MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]

-1.1e-01

2.5e-01

1.9e+00

—

1.1e+00

3.0e-01

-6.2e-02

cases:18.02%

controls:19.64%

cases:19.82%

controls:16.13%

cases:16.22%

controls:2.70%

—

cases:8.33%

controls:2.80%

cases:23.23%

controls:18.25%

cases:35.29%

controls:36.73%

218

892

179

931

1080

—

1078

196

878

335

577

Examination and observation for other specified reasons
Z04.8 [45552063]

—

1.9e+00

—

cases:9.41%

controls:1.54%

—

898

Microorganisms panel - Urine sediment
58435-9 [40761536]

—

1.9e+00

—

cases:9.41%

controls:1.54%

—

898

Intravenous
ZX120 [2001311495]

—

1.9e+00

—

cases:9.41%

controls:1.54%

—

898

CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]

—

1.2e+00

—

1.9e+00

7.4e-01

—

cases:4.50%

controls:1.44%

—

cases:8.08%

controls:1.30%

cases:9.41%

controls:4.71%

—

106

1094

—

1060

869

lactulose; oral
A06AD11 [21600571]

—

1.2e+00

—

1.3e+00

1.9e+00

—

cases:4.50%

controls:1.44%

—

cases:5.05%

controls:1.49%

cases:12.94%

controls:2.19%

—

106

1094

—

1058

892

Sedation and analgesia
WX002 [2001310758]

7.6e-01

—

1.9e+00

cases:4.50%

controls:2.16%

—

cases:17.65%

controls:3.18%

106

1086

—

883

Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]

—

1.8e+00

—

1.3e+00

—

cases:7.21%

controls:1.26%

—

cases:11.76%

controls:3.51%

—

103

1096

—

880

Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]

5.7e-03

-2.7e-01

1.8e+00

—

-3.4e-01

1.9e-01

cases:19.82%

controls:19.73%

cases:9.91%

controls:12.61%

cases:9.01%

controls:1.62%

—

cases:10.10%

controls:13.69%

cases:36.47%

controls:32.13%

219

891

140

100

970

101

1092

—

147

927

293

619

Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]

—

1.8e+00

—

cases:14.12%

controls:2.74%

—

887

General anesthesia, balanced
WX408 [2001310808]

7.0e-01

—

1.7e+00

cases:6.31%

controls:3.24%

—

cases:15.29%

controls:3.07%

104

1074

—

884

Essential (primary) hypertension
I10 [45591453]

2.6e-01

3.6e-01

1.3e+00

—

1.7e+00

9.5e-02

3.4e-01

cases:27.03%

controls:22.16%

cases:17.12%

controls:12.61%

cases:8.11%

controls:2.25%

—

cases:9.26%

controls:1.89%

cases:15.15%

controls:13.97%

cases:34.12%

controls:26.86%

246

864

140

970

102

1085

—

1088

150

924

245

667

Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]

-4.8e-03

2.2e-01

1.6e+00

—

1.1e+00

3.7e-01

3.8e-01

cases:25.23%

controls:25.32%

cases:26.13%

controls:22.16%

cases:18.02%

controls:4.05%

—

cases:9.26%

controls:3.34%

cases:30.30%

controls:23.18%

cases:52.94%

controls:43.53%

281

829

246

864

1065

—

1072

249

825

397

515

Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]

-1.4e-02

2.6e-01

1.6e+00

—

1.0e+00

3.3e-01

4.2e-01

cases:25.23%

controls:25.50%

cases:27.03%

controls:22.16%

cases:17.12%

controls:3.96%

—

cases:9.26%

controls:3.52%

cases:30.30%

controls:23.84%

cases:54.12%

controls:43.75%

283

827

246

864

1066

—

1070

256

818

399

513

Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]

-8.4e-02

2.7e-01

1.6e+00

—

9.9e-01

4.7e-01

3.5e-01

cases:25.23%

controls:26.85%

cases:28.83%

controls:23.60%

cases:21.62%

controls:5.32%

—

cases:10.19%

controls:4.06%

cases:35.35%

controls:25.51%

cases:54.12%

controls:45.50%

298

812

262

848

1051

—

1064

274

800

415

497

Sensorineural hearing loss, bilateral
H90.3 [45576850]

1.3e-01

—

1.6e+00

cases:4.50%

controls:3.96%

—

cases:10.59%

controls:2.41%

106

1066

—

890

Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]

—

1.7e+00

—

1.6e+00

—

cases:6.31%

controls:1.26%

—

cases:10.59%

controls:2.41%

—

104

1096

—

890

Fall on same level from slipping, tripping and stumbling
W01 [45756243]

1.9e-01

—

1.5e+00

6.6e-01

cases:5.41%

controls:4.50%

—

cases:10.10%

controls:2.42%

cases:11.76%

controls:6.47%

105

1060

—

1048

853

Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]

6.1e-01

—

1.5e+00

cases:7.21%

controls:4.05%

—

cases:17.65%

controls:4.61%

103

1065

—

870

Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]

1.4e-01

3.3e-01

1.5e+00

—

1.2e+00

4.6e-01

5.6e-01

cases:20.72%

controls:18.56%

cases:21.62%

controls:16.58%

cases:15.32%

controls:3.96%

—

cases:8.33%

controls:2.61%

cases:24.24%

controls:16.76%

cases:42.35%

controls:29.61%

206

904

184

926

1066

—

1080

180

894

270

642

Cathetrisation of vein
TPH04 [2001309597]

—

1.6e+00

—

1.5e+00

—

cases:4.50%

controls:0.90%

—

cases:12.94%

controls:3.29%

—

106

1100

—

882

Other specified special examinations
Z01.8 [45581003]

—

1.5e+00

—

cases:5.05%

controls:1.12%

cases:12.94%

controls:3.29%

—

1062

882

Rheumatology
66 [38004491]

6.6e-01

1.1e+00

—

1.5e+00

1.4e+00

cases:7.21%

controls:3.87%

cases:4.50%

controls:1.53%

—

cases:8.08%

controls:1.96%

cases:12.94%

controls:3.40%

103

1067

106

1093

—

1053

881

buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]

—

-1.0e+50

1.5e+00

1.4e+00

—

cases:0.00%

controls:0.45%

cases:5.05%

controls:1.12%

cases:11.76%

controls:3.07%

—

108

1104

1062

884

Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]

—

1.5e+00

—

1.4e+00

—

cases:6.31%

controls:1.44%

—

cases:11.76%

controls:3.18%

—

104

1094

—

883

omeprazole; oral, parenteral
A02BC01 [21600096]

2.1e-01

6.8e-01

—

1.4e+00

cases:7.21%

controls:5.95%

cases:4.50%

controls:2.34%

—

cases:14.12%

controls:3.95%

103

1044

106

1084

—

876

Right side
ZXA00 [2001311346]

9.0e-01

—

1.4e+00

cases:9.01%

controls:3.87%

—

cases:14.12%

controls:3.95%

101

1067

—

876

ciprofloxacin; oral, parenteral
J01MA02 [21603009]

6.9e-01

—

1.4e+00

cases:11.71%

controls:6.22%

—

cases:21.18%

controls:6.36%

1041

—

854

Lymphocytes/Leukocytes in Blood
26478-8 [3002030]

1.3e-01

6.9e-01

1.7e+00

—

1.4e+00

8.9e-01

cases:9.01%

controls:8.02%

cases:8.11%

controls:4.23%

cases:5.41%

controls:1.08%

—

cases:15.15%

controls:4.38%

cases:23.53%

controls:11.18%

101

1021

102

1063

105

1098

—

1027

102

810

ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]

6.9e-01

—

1.4e+00

cases:5.41%

controls:2.79%

—

cases:16.47%

controls:4.82%

105

1079

—

868

More than one and less than three hours
ZXE10 [2001311401]

5.8e-01

1.4e+00

—

1.4e+00

1.3e+00

cases:8.11%

controls:4.68%

cases:5.41%

controls:1.44%

—

cases:7.07%

controls:1.77%

cases:18.82%

controls:5.81%

102

1058

105

1094

—

1055

859

Chest pain, unspecified
R07.4 [45558450]

3.6e-01

—

1.3e+00

cases:6.31%

controls:4.50%

—

cases:15.29%

controls:4.82%

104

1060

—

868

Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]

4.4e-01

7.0e-01

—

1.3e+00

9.4e-01

cases:11.71%

controls:7.84%

cases:6.31%

controls:3.24%

—

cases:13.13%

controls:4.10%

cases:22.35%

controls:10.09%

1023

104

1074

—

1030

820

Physiotherapy
R4110 [2001310233]

4.2e-01

1.4e+00

—

1.1e+00

1.2e+00

cases:6.31%

controls:4.23%

cases:5.41%

controls:1.44%

—

cases:6.06%

controls:2.05%

cases:16.47%

controls:5.48%

104

1063

105

1094

—

1052

862

metronidazole; oral, rectal
P01AB01 [21604857]

4.8e-01

—

1.2e+00

cases:9.01%

controls:5.77%

—

cases:15.29%

controls:5.04%

101

1046

—

866

Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]

7.3e-01

—

1.2e+00

cases:9.91%

controls:5.05%

—

cases:23.53%

controls:8.55%

100

1054

—

834

Telephone prescription or other care instructions
WZB00 [2001310884]

—

-1.0e+50

1.2e+00

—

cases:0.00%

controls:1.30%

cases:15.29%

controls:5.37%

—

1060

863

hydrocortisone
S02BA01 [21605166]

1.1e+00

9.5e-01

—

-2.6e-02

cases:15.32%

controls:5.50%

cases:5.41%

controls:2.16%

—

cases:5.88%

controls:6.03%

1049

105

1086

—

857

Differential panel, method unspecified - Blood
69738-3 [42870588]

1.5e-01

—

1.4e+00

1.1e+00

cases:5.41%

controls:4.68%

—

cases:9.09%

controls:2.33%

cases:20.00%

controls:7.57%

105

1058

—

1049

843

Emergency Medicine
93 [38004510]

3.1e-01

1.1e+00

—

8.2e-01

6.7e-01

cases:13.51%

controls:10.27%

cases:13.51%

controls:5.05%

—

cases:13.13%

controls:6.24%

cases:27.06%

controls:16.01%

114

996

1054

—

1007

146

766

amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]

5.8e-01

1.4e+00

—

1.2e+00

1.1e+00

cases:11.71%

controls:6.94%

cases:7.21%

controls:1.89%

—

cases:5.05%

controls:1.58%

cases:22.35%

controls:8.99%

1033

103

1089

—

1057

830

hydrocortisone
C05AA01 [21601608]

1.0e+00

7.9e-01

—

2.3e-02

cases:16.22%

controls:6.58%

cases:5.41%

controls:2.52%

—

cases:7.06%

controls:6.91%

1037

105

1082

—

849

hydrocortisone
A07EA02 [21600654]

1.0e+00

7.9e-01

—

2.3e-02

cases:16.22%

controls:6.58%

cases:5.41%

controls:2.52%

—

cases:7.06%

controls:6.91%

1037

105

1082

—

849

hydrocortisone aceponate
D07AC16 [21602135]

1.0e+00

8.3e-01

—

4.0e-02

cases:16.22%

controls:6.58%

cases:5.41%

controls:2.43%

—

cases:7.06%

controls:6.80%

1037

105

1083

—

850

hydrocortisone
D07AA02 [21602102]

1.0e+00

8.3e-01

—

4.0e-02

cases:16.22%

controls:6.58%

cases:5.41%

controls:2.43%

—

cases:7.06%

controls:6.80%

1037

105

1083

—

850

hydrocortisone buteprate
D07AB11 [21602115]

1.0e+00

8.3e-01

—

4.0e-02

cases:16.22%

controls:6.58%

cases:5.41%

controls:2.43%

—

cases:7.06%

controls:6.80%

1037

105

1083

—

850

hydrocortisone butyrate
D07AB02 [21602106]

1.0e+00

8.3e-01

—

4.0e-02

cases:16.22%

controls:6.58%

cases:5.41%

controls:2.43%

—

cases:7.06%

controls:6.80%

1037

105

1083

—

850

General Practice
1 [38004446]

7.1e-01

8.6e-01

1.5e+00

1.0e+50

1.5e+00

5.7e-01

9.2e-01

cases:23.42%

controls:13.06%

cases:14.41%

controls:6.67%

cases:4.50%

controls:1.08%

cases:4.50%

controls:0.00%

cases:4.63%

controls:1.08%

cases:11.11%

controls:6.61%

cases:32.94%

controls:16.34%

145

965

1036

106

1098

106

1110

103

1097

1003

149

763

Orthopedic Surgery
20 [38004465]

-1.7e-01

6.4e-01

—

8.5e-01

9.0e-01

cases:14.41%

controls:16.58%

cases:9.91%

controls:5.50%

—

cases:12.12%

controls:5.59%

cases:30.59%

controls:15.13%

184

926

100

1049

—

1014

138

774

Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]

-1.8e-01

5.9e-01

—

-1.0e+50

2.8e-01

8.9e-01

cases:9.91%

controls:11.62%

cases:10.81%

controls:6.31%

—

cases:0.00%

controls:0.90%

cases:10.10%

controls:7.82%

cases:34.12%

controls:17.54%

129

100

981

1040

—

108

1099

990

160

752

amoxicillin; oral, parenteral
J01CA04 [21602823]

1.6e-01

3.7e-01

—

6.8e-01

8.5e-01

cases:23.42%

controls:20.63%

cases:9.01%

controls:6.40%

—

cases:11.11%

controls:5.96%

cases:34.12%

controls:18.09%

229

881

101

1039

—

1010

165

747

Telehealth
OMOP5556618 [722455]

2.6e-01

2.0e-01

1.1e+00

—

-7.9e-02

7.8e-01

cases:25.23%

controls:20.72%

cases:12.61%

controls:10.54%

cases:5.41%

controls:1.80%

—

cases:11.11%

controls:11.92%

cases:48.24%

controls:29.93%

230

880

117

993

105

1090

—

128

946

273

639

chloramphenicol
S01AA01 [21603554]

—

6.7e-01

—

cases:14.12%

controls:7.79%

—

841

Calcium.ionized [Moles/volume] in Venous blood
41645-3 [3033705]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

111

1105

—

Neoplasm of uncertain or unknown behaviour: Skin
D48.5 [45586113]

-1.0e+50

—

cases:0.00%

controls:0.72%

cases:0.00%

controls:0.54%

—

111

1102

111

1104

—

Outlining of treatment with patient or their family members
SPAT1276 [2001700377]

—

-1.0e+50

—

cases:0.00%

controls:0.55%

—

907

fluticasone; inhalant
R03BA05 [21603288]

7.3e-01

1.1e+00

—

1.3e+00

cases:7.21%

controls:3.60%

cases:4.50%

controls:1.53%

—

cases:9.41%

controls:2.74%

103

1070

106

1093

—

887

Supine thorax X-ray examination
GD1QA [2001303648]

—

1.4e+00

—

cases:8.24%

controls:2.19%

—

892

Other complicated root filling
SGB30 [2001310390]

-1.0e+50

—

cases:0.00%

controls:1.17%

—

111

1097

—

Other and unspecified cirrhosis of liver
K74.6 [45538546]

1.0e+50

cases:4.50%

controls:0.00%

cases:11.71%

controls:0.00%

cases:7.21%

controls:0.00%

cases:5.41%

controls:0.00%

cases:5.56%

controls:0.00%

cases:14.14%

controls:0.00%

cases:15.29%

controls:0.00%

106

1110

103

1110

105

1110

102

1109

1074

912

Chronic obstructive pulmonary disease with acute exacerbation, unspecified
J44.1 [45601132]

-1.0e+50

—

cases:0.00%

controls:0.54%

—

111

1104

—

Paranasal sinuses X-ray examination without contrast
DM1AA [2001301740]

—

-1.0e+50

—

cases:0.00%

controls:0.77%

—

905

Labeling mammary gland pathology with ultrasound guidance
HA4AT [2001303990]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

111

1105

—

Spontaneous vertex delivery
O80.0 [45577661]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.44%

—

cases:0.00%

controls:0.56%

—

111

1094

—

1068

—

Bacteria [Presence] in Urine
87829-8 [36304419]

4.3e-02

7.2e-01

—

8.5e-01

cases:4.50%

controls:4.32%

cases:4.50%

controls:2.25%

—

cases:11.76%

controls:5.37%

106

1062

106

1085

—

863

Polymyalgia rheumatica
M35.3 [45533830]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.72%

cases:0.00%

controls:0.45%

—

cases:0.00%

controls:0.84%

cases:0.00%

controls:1.21%

111

1102

111

1105

—

1065

901

vilanterol and fluticasone furoate
R03AK10 [43534841]

—

-1.0e+50

—

cases:0.00%

controls:0.99%

—

903

Primary open-angle glaucoma
H40.1 [45533312]

—

-1.0e+50

—

cases:0.00%

controls:0.66%

—

906

Intraoperative use of conventional X-ray imaging
ZXM10 [2001311446]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

111

1105

—

SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]

-1.0e+50

—

cases:0.00%

controls:1.08%

—

111

1098

—

Mental and behavioural disorders due to use of alcohol, Harmful use
F10.1 [45595844]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.54%

—

cases:0.00%

controls:0.47%

cases:0.00%

controls:1.54%

—

111

1104

—

1069

898

Breast cancer
115 [2001600115]

-1.0e+50

—

cases:0.00%

controls:0.81%

—

111

1101

—

pramipexole; oral
N04BC05 [21604477]

—

-1.0e+50

—

cases:0.00%

controls:0.54%

—

111

1104

—

Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.45%

—

cases:0.00%

controls:0.74%

—

111

1105

—

1066

—

Open wound of wrist and hand, part unspecified
S61.9 [45554740]

-1.0e+50

—

cases:0.00%

controls:0.54%

—

111

1104

—

General and Unspecified, Preventive immunization/medic
A44 [2002000178]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.81%

—

cases:0.00%

controls:0.66%

111

1101

—

906

Other specified counselling
Z71.8 [45581061]

4.6e-01

—

8.1e-01

cases:4.50%

controls:2.88%

—

cases:8.24%

controls:3.84%

106

1078

—

877

Potassium [Moles/volume] in Venous blood
39789-3 [3041354]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

111

1105

—

fluocortolone
D07AC05 [21602124]

—

-1.0e+50

—

cases:0.00%

controls:0.54%

—

111

1104

—

miconazole
S02AA13 [21605159]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.90%

—

cases:0.00%

controls:0.55%

111

1100

—

907

Erythrocyte [DistWidth] in Red Blood Cells by Automated count
788-0 [3019897]

—

-1.0e+50

—

cases:0.00%

controls:0.77%

—

905

Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]

—

2.2e+00

—

7.2e-01

—

cases:4.50%

controls:0.54%

—

cases:9.41%

controls:4.82%

—

106

1104

—

868

indometacin; oral, parenteral, rectal
M01AB01 [21603941]

—

-1.0e+50

—

cases:0.00%

controls:0.77%

—

905

Acute pain
R52.0 [45573031]

—

-1.0e+50

—

cases:0.00%

controls:0.77%

—

905

aciclovir
D06BB03 [21602085]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.72%

—

cases:0.00%

controls:0.55%

111

1102

—

907

Cerebral infarction due to embolism of cerebral arteries
I63.4 [45591475]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.54%

—

cases:0.00%

controls:0.55%

111

1104

—

907

Counselling and guidance related to nutrition and weight management
SPAT1306 [2001700407]

—

-1.0e+50

—

cases:0.00%

controls:0.63%

—

108

1102

—

atorvastatin; oral
C10AA05 [21601860]

6.2e-02

-2.6e-01

—

-3.3e-01

-6.4e-02

cases:11.71%

controls:11.08%

cases:7.21%

controls:9.19%

—

cases:7.07%

controls:9.59%

cases:14.12%

controls:14.91%

123

987

102

103

1008

—

103

971

136

776

ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]

3.1e-01

—

-1.0e+50

—

cases:6.31%

controls:4.68%

—

cases:0.00%

controls:0.54%

—

104

1058

—

111

1104

—

Cardiovascular sympt/complt other
K29 [2002000556]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

111

1105

—

solifenacin; oral
G04BD08 [21602641]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.63%

—

cases:0.00%

controls:0.56%

—

111

1103

—

1068

—

Lump/swelling localized
S04 [2002000969]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

111

1102

—

Diarrhoea
D11 [2002000310]

—

-1.0e+50

—

cases:0.00%

controls:0.45%

—

111

1105

—

Biopsy of prostate with ultrasoudnguidance
KE1AT [2001306172]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.45%

cases:0.00%

controls:0.45%

—

cases:0.00%

controls:0.55%

111

1105

111

1105

—

907

Photography of fundus of eye
XCK10 [2001301381]

5.6e-01

—

cases:4.50%

controls:2.61%

—

106

1081

—

Radiotherapy with large shaped fields - isocentric therapy
ZX012 [2001311468]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

111

1102

—

Memory test
SPAT1053 [2001700154]

—

-1.0e+50

—

cases:0.00%

controls:0.84%

—

1065

—

isosorbide mononitrate; oral
C01DA14 [21600324]

9.2e-02

2.6e-01

—

cases:5.41%

controls:4.95%

cases:5.41%

controls:4.23%

—

105

1055

105

1063

—

Derangement of meniscus due to old tear or injury
M23.2 [45591779]

—

-1.0e+50

—

cases:0.00%

controls:0.45%

—

111

1105

—

Cardiodefibrillation
TFP20 [2001303224]

—

-1.0e+50

—

cases:0.00%

controls:0.77%

—

905

Fracture of tooth, open
S02.51 [45755762]

-1.0e+50

—

cases:0.00%

controls:0.63%

—

111

1103

—

Arthrocentesis, unspecified region, unspecified region
TNX10 [2001308560]

—

-1.0e+50

—

cases:0.00%

controls:0.54%

—

111

1104

—

Glaucoma suspect
H40.0 [45567051]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:1.71%

cases:0.00%

controls:0.81%

—

cases:0.00%

controls:0.74%

cases:0.00%

controls:0.77%

111

1091

111

1101

—

1066

905

mirtazapine; oral
N06AX11 [21604740]

4.3e-01

3.5e-01

—

5.5e-01

cases:9.01%

controls:6.04%

cases:5.41%

controls:3.87%

—

cases:11.76%

controls:7.13%

101

1043

105

1067

—

847

levofloxacin
S01AE05 [43534860]

—

-1.0e+50

—

9.1e-01

—

cases:0.00%

controls:0.45%

—

cases:7.06%

controls:2.96%

—

111

1105

—

885

Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2874-6 [3023465]

—

-1.0e+50

—

cases:0.00%

controls:0.77%

—

905

Spinalanesthesia
WX320 [2001310799]

—

1.2e+00

—

cases:8.24%

controls:2.74%

—

887

Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]

-1.0e+50

—

1.4e+00

cases:0.00%

controls:1.62%

—

cases:9.41%

controls:2.52%

111

1092

—

889

Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]

-7.8e-02

9.3e-01

—

7.6e-01

4.8e-01

cases:7.21%

controls:7.75%

cases:7.21%

controls:2.97%

—

cases:7.07%

controls:3.45%

cases:17.65%

controls:11.73%

103

1024

103

1077

—

1037

107

805

imiquimod
D06BB10 [21602092]

—

-1.0e+50

—

cases:0.00%

controls:0.47%

—

1069

—

Extraction of root of tooth
EBA30 [2001301929]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.63%

—

cases:0.00%

controls:1.32%

111

1103

—

900

Teeth/gum disease
D82 [2002000380]

4.9e-01

—

1.6e-02

cases:6.31%

controls:3.96%

—

cases:8.24%

controls:8.11%

104

1066

—

838

Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
C50.41 [2000501002]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:1.08%

cases:0.00%

controls:0.72%

—

cases:0.00%

controls:0.65%

cases:0.00%

controls:1.21%

111

1098

111

1102

—

1067

901

Other function in accordance with NCSP classification
SPAT1291 [2001700392]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

111

1105

—

Dental X-ray, bite-wing X-ray on one side of the mouth
EB1SA [2001301918]

4.7e-02

—

-6.9e-02

cases:6.31%

controls:6.04%

—

cases:8.24%

controls:8.77%

104

1043

—

832

Other Alzheimer disease
G30.8 [45605532]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.45%

cases:0.00%

controls:0.45%

—

cases:0.00%

controls:0.88%

111

1105

111

1105

—

904

Cardiac ultrasound examination through oesophagus
FM1BE [2001303285]

-1.0e+50

—

cases:0.00%

controls:0.63%

—

111

1103

—

Urination problems other
U05 [2002001140]

—

-1.0e+50

—

cases:0.00%

controls:0.45%

—

111

1105

—

acebutolol; oral, parenteral
C07AB04 [21601686]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

111

1105

—

Alveolitis of jaws
K10.3 [45591576]

—

-1.0e+50

—

cases:0.00%

controls:0.55%

—

907

sumatriptan; nasal, oral, parenteral, rectal
N02CC01 [21604376]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.81%

—

cases:0.00%

controls:0.84%

—

111

1101

—

1065

—

chloramphenicol
S03AA08 [21605197]

—

6.7e-01

—

cases:14.12%

controls:7.79%

—

841

Oral Surgery
19 [38004464]

—

1.8e+00

—

cases:7.06%

controls:1.21%

—

901

Carpal tunnel syndrome
G56.0 [45566891]

1.7e+00

—

cases:6.31%

controls:1.26%

—

104

1096

—

Nuclear Ab [Titer] in Serum
29953-7 [3037522]

1.3e+00

—

1.0e+50

—

1.5e+00

cases:4.50%

controls:1.26%

—

cases:6.31%

controls:0.00%

—

cases:9.41%

controls:2.19%

106

1096

—

104

1110

—

892

Ultrasound examination of uterus and parametria
LC2AE [2001306543]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.99%

—

cases:0.00%

controls:0.88%

111

1099

—

904

Body mass index
60621009 [4245997]

-7.5e-01

—

-1.0e+50

—

1.0e+50

cases:9.91%

controls:18.83%

—

cases:0.00%

controls:0.63%

—

cases:17.65%

controls:0.00%

209

100

901

—

111

1103

—

912

Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]

—

1.2e+00

7.2e-01

—

cases:6.06%

controls:1.96%

cases:8.24%

controls:4.17%

—

1053

874

scopolamine
A04AD01 [21600499]

—

-1.0e+50

—

cases:0.00%

controls:0.88%

—

904

nedocromil; inhalant
R03BC03 [21603299]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

111

1105

—

duloxetine; oral
N06AX21 [21604749]

—

-1.0e+50

—

cases:0.00%

controls:0.54%

—

108

1103

—

Hyperkalaemia
E87.5 [45537990]

—

-1.0e+50

—

cases:0.00%

controls:0.55%

—

907

Pelvis X-ray examination
NE1AA [2001307792]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

111

1102

—

Breast Pathology biopsy report
66110-8 [40768793]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.45%

—

cases:0.00%

controls:0.55%

111

1105

—

907

metformin; oral
A10BA02 [21600747]

7.3e-01

5.9e-01

8.1e-01

—

4.6e-01

2.1e-01

1.3e-01

cases:23.42%

controls:12.79%

cases:18.92%

controls:11.44%

cases:7.21%

controls:3.33%

—

cases:4.63%

controls:2.98%

cases:14.14%

controls:11.82%

cases:14.12%

controls:12.61%

142

968

127

983

103

1073

—

103

1076

127

947

115

797

Albumin [Mass/volume] in Urine
1754-1 [3012516]

3.8e-01

—

4.6e-01

cases:7.21%

controls:5.05%

—

cases:16.47%

controls:11.07%

103

1054

—

101

811

lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]

—

-1.0e+50

—

cases:0.00%

controls:0.88%

—

904

Haemoptysis
R04.2 [45577777]

-1.0e+50

—

cases:0.00%

controls:0.81%

—

111

1101

—

Other dorsalgia
M54.8 [45538790]

—

-1.0e+50

—

cases:0.00%

controls:0.55%

—

907

dexrabeprazole
A02BC07 [45893509]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.62%

—

cases:0.00%

controls:0.54%

—

111

1092

—

111

1104

—

Geriatric Medicine
38 [38004478]

-1.0e+50

—

cases:0.00%

controls:1.35%

—

111

1095

—

Complicated extraction of tooth
EBA05 [2001301924]

—

8.7e-01

—

cases:7.06%

controls:3.07%

—

884

Lumbar spine and sacrum CT examination
NA3AD [2001307027]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

111

1105

—

CT of paranasal sinuses and face area
DM1AD [2001301741]

—

-1.0e+50

—

cases:0.00%

controls:0.66%

—

906

candesartan; oral
C09CA06 [21601829]

1.4e-01

4.0e-01

—

2.0e-01

—

cases:7.21%

controls:6.31%

cases:8.11%

controls:5.59%

—

cases:7.07%

controls:5.87%

—

103

1040

102

1048

—

1011

—

pneumococcus, purified polysaccharides antigen conjugated
J07AL02 [21601313]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.89%

—

cases:0.00%

controls:0.65%

—

111

1089

—

1067

—

Other general examinations
Z00.8 [45581001]

—

-1.0e+50

—

cases:0.00%

controls:0.74%

cases:0.00%

controls:1.64%

—

1066

897

Acute suppurative otitis media
H66.0 [45572040]

—

-1.0e+50

—

cases:0.00%

controls:0.56%

cases:0.00%

controls:0.55%

—

1068

907

Reticulocytes [#/volume] in Blood
14196-0 [3023520]

—

1.6e+00

—

cases:7.06%

controls:1.54%

—

898

travoprost
S01EE04 [21603713]

—

-1.0e+50

—

cases:0.00%

controls:0.55%

—

907

Remote contact by phone
ZYC01 [2001311579]

—

-1.0e+50

—

cases:0.00%

controls:0.47%

—

1069

—

metoprolol; oral, parenteral
C07AB02 [21601684]

1.1e-01

1.4e-01

—

1.0e-01

1.1e-01

cases:8.11%

controls:7.30%

cases:7.21%

controls:6.31%

—

cases:7.07%

controls:6.42%

cases:8.24%

controls:7.46%

102

1029

103

1040

—

1005

844

promethazine, combinations
R06AD52 [21603489]

—

-1.0e+50

—

cases:0.00%

controls:0.77%

—

905

Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10886-0 [3005013]

—

-1.0e+50

—

cases:0.00%

controls:1.68%

—

1056

—

Wedge excision of mammary gland
HAB40 [2001303928]

-1.0e+50

—

cases:0.00%

controls:0.81%

—

111

1101

—

intermediate-acting sulfonamides - combinations
J01EC20 [21602948]

—

-1.0e+50

—

cases:0.00%

controls:0.77%

—

905

pH of Arterial blood
2744-1 [3019977]

—

-1.0e+50

—

1.2e+00

—

cases:0.00%

controls:0.45%

—

cases:8.24%

controls:2.74%

—

111

1105

—

887

Caries of cementum
K02.2 [45591568]

-1.0e+50

—

cases:0.00%

controls:0.90%

—

111

1100

—

Ear pain/earache
H01 [2002000475]

—

-1.0e+50

—

cases:0.00%

controls:1.32%

—

900

Preparing and fitting the occlusal splint in the mouth
SHB00 [2001310410]

-1.0e+50

—

cases:0.00%

controls:0.54%

—

111

1104

—

Biliary cirrhosis, unspecified
K74.5 [45533615]

—

1.0e+50

—

cases:100.00%

controls:0.00%

cases:19.44%

controls:0.00%

cases:35.35%

controls:0.00%

cases:30.59%

controls:0.00%

—

111

1110

1109

1074

912

Immunohistochemistry procedure
117617002 [4035726]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.72%

—

cases:0.00%

controls:0.47%

—

111

1102

—

1069

—

benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]

5.5e-01

5.4e-01

—

1.2e+00

7.2e-01

cases:19.82%

controls:12.43%

cases:6.31%

controls:3.78%

—

cases:8.08%

controls:2.70%

cases:23.53%

controls:13.05%

138

972

104

1068

—

1045

119

793

Otolaryngology
4 [38004449]

-9.3e-02

8.1e-01

—

-1.0e+50

1.4e-01

3.2e-01

cases:11.71%

controls:12.70%

cases:8.11%

controls:3.78%

—

cases:0.00%

controls:0.81%

cases:6.06%

controls:5.31%

cases:12.94%

controls:9.76%

141

969

102

1068

—

108

1100

1017

823

Observation for other suspected diseases and conditions
Z03.89 [2000503757]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.54%

—

cases:0.00%

controls:1.75%

—

111

1104

—

896

erythromycin; oral, parenteral
J01FA01 [21602970]

-1.0e+50

—

cases:0.00%

controls:0.63%

—

111

1103

—

Gynaecological examination (general)(routine)
Z01.4 [45542395]

—

-1.0e+50

1.3e+00

—

cases:0.00%

controls:0.47%

cases:5.88%

controls:1.64%

—

1069

897

hydroxychloroquine; oral
P01BA02 [21604889]

—

-1.0e+50

—

8.8e-01

—

cases:0.00%

controls:0.63%

—

cases:5.88%

controls:2.52%

—

108

1102

—

889

platelet aggregation inhibitors excl. heparin - combinations
B01AC30 [21601005]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.17%

—

cases:0.00%

controls:1.12%

cases:0.00%

controls:1.97%

—

111

1097

—

1062

894

apixaban; oral
B01AF02 [43534762]

—

6.4e-01

-1.0e+50

—

cases:4.50%

controls:2.43%

cases:0.00%

controls:1.35%

—

106

1083

111

1095

—

ketorolac
S01BC05 [21603643]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

111

1102

—

Rheumatism, unspecified
M79.0 [45567658]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.45%

—

cases:0.00%

controls:0.55%

111

1105

—

907

hydrocortisone and antiseptics
D07BA04 [21602146]

—

-1.0e+50

—

cases:0.00%

controls:0.74%

cases:0.00%

controls:2.08%

—

1066

893

Gout, unspecified
M10.9 [45543454]

—

-1.0e+50

—

cases:0.00%

controls:0.88%

—

904

Periodontitis pronounced
K05.31 [2000502729]

—

-1.0e+50

—

1.6e+00

—

cases:0.00%

controls:0.54%

—

cases:8.24%

controls:1.86%

—

111

1104

—

895

Extensive global examination
SPAT1360 [2001700461]

—

-1.0e+50

—

cases:0.00%

controls:0.47%

—

1069

—

Excision of other lesion extending through all layers of skin in lower limb
QDE10 [2001309980]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

111

1105

—

Repeated or continuing anesthesia shots throug a catheter
WX602 [2001310813]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

111

1102

—

Sampling
SPAT1263 [2001700364]

-1.3e-02

—

3.1e-03

cases:7.21%

controls:7.30%

—

cases:11.76%

controls:11.73%

103

1029

—

107

805

insulin lispro; parenteral
A10AD04 [21600732]

—

-1.0e+50

—

cases:0.00%

controls:0.54%

—

111

1104

—

zolmitriptan; nasal, oral
N02CC03 [21604378]

-1.0e+50

—

cases:0.00%

controls:0.63%

cases:0.00%

controls:0.45%

—

111

1103

111

1105

—

insulin lispro; parenteral
A10AC04 [21600726]

—

-1.0e+50

—

cases:0.00%

controls:0.54%

—

111

1104

—

Presence of intraocular lens
Z96.1 [45585885]

1.1e+00

—

9.1e-01

cases:6.31%

controls:2.16%

—

cases:7.06%

controls:2.96%

104

1086

—

885

Detailed morfological ultrasound examination of fetus
MA2HE [2001306836]

-1.0e+50

—

cases:0.00%

controls:0.72%

cases:0.00%

controls:0.45%

—

111

1102

111

1105

—

dexamethasone
S03BA01 [21605201]

—

-1.0e+50

—

cases:0.00%

controls:0.45%

—

111

1105

—

Impacted cerumen
H61.2 [45562307]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.45%

—

cases:0.00%

controls:0.88%

—

111

1105

—

904

nystatin
D01AA01 [21601911]

—

-1.0e+50

—

cases:0.00%

controls:1.32%

—

900

olanzapine; oral, parenteral
N05AH03 [21604543]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.54%

—

cases:0.00%

controls:0.99%

111

1104

—

903

Open wound of scalp
S01.0 [45592468]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.63%

—

cases:0.00%

controls:0.88%

111

1103

—

904

ursodeoxycholic acid; oral
A05AA02 [21600513]

—

1.0e+50

—

cases:18.92%

controls:0.00%

—

1110

—

paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]

7.6e-01

—

-1.0e+50

—

cases:5.41%

controls:2.61%

—

cases:0.00%

controls:0.74%

—

105

1081

—

1066

—

Small restoration
SFA00 [2001310357]

—

-1.0e+50

—

cases:0.00%

controls:0.63%

—

111

1103

—

fluticasone, combinations
R01AD58 [43534837]

—

-1.0e+50

—

cases:0.00%

controls:1.02%

—

1063

—

Base excess in Arterial blood by calculation
1925-7 [3003396]

—

-1.0e+50

—

1.2e+00

—

cases:0.00%

controls:0.54%

—

cases:8.24%

controls:2.74%

—

111

1104

—

887

Testosterone [Moles/volume] in Serum or Plasma
14913-8 [3017446]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.54%

—

cases:0.00%

controls:0.77%

111

1104

—

905

Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]

3.7e-01

—

6.5e-01

9.0e-01

cases:8.11%

controls:5.77%

—

cases:5.05%

controls:2.70%

cases:16.47%

controls:7.46%

102

1046

—

1045

844

Other blockage of nerve
WX290 [2001310792]

8.8e-02

—

-1.0e+50

—

8.5e-01

cases:8.11%

controls:7.48%

—

cases:0.00%

controls:0.54%

—

cases:16.47%

controls:7.79%

102

1027

—

111

1104

—

841

enoxaparin; parenteral
B01AB05 [21600976]

—

1.9e-01

—

cases:8.24%

controls:6.91%

—

849

Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]

-3.8e-01

—

8.1e-01

5.2e-01

cases:5.41%

controls:7.75%

—

cases:7.07%

controls:3.26%

cases:16.47%

controls:10.53%

105

1024

—

1039

816

Mitral (valve) prolapse
I34.1 [45552788]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

111

1105

—

ketotifen
S01GX08 [21605092]

—

-1.0e+50

—

cases:0.00%

controls:0.55%

—

907

Cystitis/urinary infection other
U71 [2002001191]

—

-1.0e+50

—

cases:0.00%

controls:0.47%

cases:0.00%

controls:0.77%

—

1069

905

phenylpropanolamine, combinations; oral
R01BA51 [21603212]

—

-1.0e+50

—

cases:0.00%

controls:0.77%

—

905

Cystatin C [Mass/volume] in Serum or Plasma
33863-2 [3030366]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

111

1105

—

Assessment of need for oral health care, standard
SAD01 [2001310287]

—

-1.0e+50

—

cases:0.00%

controls:0.47%

cases:0.00%

controls:1.32%

—

1069

900

Dysuria/painful urination
U01 [2002001137]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.90%

—

cases:0.00%

controls:0.65%

—

111

1100

—

1067

—

General anaesthesia
WX402 [2001310806]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:2.79%

—

cases:0.00%

controls:0.56%

—

111

1079

—

1068

—

Rehabilitation for hearing problems
R4135 [2001310236]

-1.0e+50

—

cases:0.00%

controls:0.54%

—

111

1104

—

nitrofurantoin; oral
J01XE01 [21603058]

—

-1.0e+50

—

cases:0.00%

controls:0.93%

—

1064

—

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3013742) Prealbumin [Mass/volume] in Serum or Plasma

108

13.61

44.72

5.8

2.9

0.18

0.21

g/l

2.89

102

(3037522) Nuclear Ab [Titer] in Serum

137

8.06

27.57

1.6

1.4

1056.00

564.85

titre

0.91

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

106

5.77

16.93

1.7

1.4

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

6.05

16.81

1.6

1.4

—

(40768441) Liver Pathology biopsy report

22.47

15.44

2.6

1.3

—

(3021952) Alkaline phosphatase isoenzymes [Enzymatic activity/volume] in Serum or Plasma by Heat stability

21.22

14.51

1.6

1.2

—

(3032080) INR in Blood by Coagulation assay

534

4.62

10.17

23.4

15.2

1.25

inr

0.02

450

(3003265) Liver kidney microsomal Ab [Titer] in Serum by Immunofluorescence

13.12

9.42

1.8

1.4

—

(3027945) Reticulocytes/Erythrocytes in Blood

143

3.66

9.07

2.5

3.0

2.19

1.80

1.27

129

(3007164) IgA [Mass/volume] in Serum or Plasma

208

3.30

8.50

1.8

1.5

3.30

2.73

g/l

0.73

118

(3007080) Epstein Barr virus nuclear IgG Ab [Units/volume] in Serum

11.36

8.33

1.9

1.7

221.75

200.00

u/ml

—

(3027529) Toxoplasma gondii IgM Ab [Units/volume] in Serum

18.99

8.28

1.3

1.1

—

(3016650) Hepatitis A virus Ab [Presence] in Serum

12.12

8.06

1.0

—

(3048929) Epstein Barr virus Ab [Presence] in Serum

8.52

8.04

1.8

1.7

—

(3026910) Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma

606

4.03

7.77

14.6

3.4

131.18

51.42

u/l

5.15

565

(3005757) Coagulation factor V activity actual/normal in Platelet poor plasma by Coagulation assay

21.76

7.27

7.3

7.0

79.30

104.20

—

(3001604) Monocytes [#/volume] in Blood

525

3.30

7.23

12.2

5.9

0.54

0.60

e9/l

1.70

438

(42870588) Differential panel, method unspecified - Blood

352

2.93

7.16

12.9

5.6

—

(3006315) Basophils [#/volume] in Blood

528

3.27

7.10

12.2

5.9

0.05

0.04

e9/l

0.56

440

(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma

580

3.50

7.07

14.6

7.3

1.20

1.21

mmol/l

0.72

493

(3013115) Eosinophils [#/volume] in Blood

539

3.30

7.05

12.8

6.4

0.22

0.18

e9/l

1.15

464

(3015399) Transferrin receptor.soluble [Mass/volume] in Serum or Plasma

291

2.87

6.91

3.8

2.3

5.38

3.01

mg/l

1.42

255

(3019198) Lymphocytes [#/volume] in Blood

534

3.20

6.84

12.2

6.0

1.55

1.94

e9/l

1.31

467

(3013327) Hepatitis A virus IgM Ab [Presence] in Serum

11.04

6.72

1.0

—

(3023420) DNA double strand Ab [Units/volume] in Serum

4.60

6.63

2.2

1.7

1.82

6.55

iu/ml

—

(3017918) Cytomegalovirus IgG Ab [Titer] in Serum or Plasma

7.84

6.45

1.7

1.5

—

(3010130) Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma

8.50

6.33

1.8

1.4

164.88

152.87

au/ml

—

(40768797) Stomach Pathology biopsy report

162

2.93

6.16

1.4

1.3

—

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

5.85

5.98

1.8

1.5

—

(3013650) Neutrophils [#/volume] in Blood by Automated count

598

3.10

5.93

14.3

10.2

4.26

4.20

e9/l

0.04

512

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

180

2.80

5.85

1.9

2.0

—

(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma

534

2.78

5.62

13.8

6.4

1.20

1.21

mmol/l

0.97

491

(3042936) Bacteria identified in Isolate by Culture

157

2.80

5.50

2.4

2.1

—

(3012095) Magnesium [Moles/volume] in Serum or Plasma

208

2.64

5.44

9.3

3.3

0.79

0.82

mmol/l

1.09

198

(3023368) Bacteria identified in Blood by Culture

305

2.50

5.29

5.3

5.0

—

(3018418) pH of Serum or Plasma

375

2.48

5.21

8.3

4.1

7.40

0.35

267

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

134

2.82

5.20

1.9

2.0

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

128

2.84

5.15

2.0

—

(3001334) Neutrophil cytoplasmic Ab [Units/volume] in Serum

4.85

4.63

1.1

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

3.09

4.56

3.2

1.7

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

118

2.70

4.38

2.1

1.6

—

(3019977) pH of Arterial blood

149

2.50

4.14

7.6

6.8

7.42

0.05

(3030692) Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection

6.89

4.07

1.1

1.3

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

3.16

4.00

1.2

1.3

—

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

4.51

3.84

1.3

1.7

—

(3003396) Base excess in Arterial blood by calculation

148

2.41

3.76

7.6

6.8

-1.03

1.10

mmol/l

1.62

130

(46237023) Hepatitis B virus core and surface Ab and surface Ag panel - Serum

4.35

3.72

1.2

—

(3000991) Gas panel - Venous blood

108

2.56

3.64

13.7

8.1

—

(3044640) Blood type and Crossmatch panel - Blood

354

2.10

3.59

4.9

2.4

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

485

2.12

3.54

6.1

2.8

—

estimate

—

(4281824) Cell count and differential, peritoneal fluid

7.38

3.41

1.6

1.0

—

(3003785) Carcinoembryonic Ag [Mass/volume] in Serum or Plasma

147

2.32

3.40

3.9

4.9

2.97

55.78

ug/l

0.60

122

(3040363) Hepatitis A virus IgG Ab [Presence] in Serum by Immunoassay

8.97

3.30

1.0

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

259

2.08

3.29

3.9

2.4

—

(3021447) Carbon dioxide [Partial pressure] in Venous blood

121

2.38

3.24

8.4

4.0

5.30

5.68

kpa

1.24

116

(3004588) Protein electrophoresis panel - Serum or Plasma

2.52

3.09

1.7

1.4

—

(3014576) Chloride [Moles/volume] in Serum or Plasma

177

2.14

3.02

7.9

6.3

105.72

104.16

mmol/l

0.94

177

(3042111) Morphology [Interpretation] in Bone marrow Narrative

4.35

2.95

1.2

1.4

—

(3035715) Granulocytes [#/volume] in Blood

5.66

2.91

5.6

1.9

2.90

5.39

e9/l

—

(3005702) Mycobacterium sp identified in Specimen by Organism specific culture

3.82

2.86

1.3

1.1

—

(3042596) Human coronavirus RNA [Presence] in Specimen by NAA with probe detection

4.70

2.85

1.0

1.4

—

(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection

4.16

2.84

1.1

1.4

—

(3025159) Blasts/Leukocytes in Blood

100

2.36

2.81

2.7

4.1

0.00

0.22

—

(3002179) Metamyelocytes/Leukocytes in Blood

2.38

2.75

2.6

3.7

1.75

0.90

—

(3017181) Myelocytes/Leukocytes in Blood

103

2.28

2.63

2.4

3.7

0.56

0.85

—

(3029080) Hemoglobin [Entitic mass] in Reticulocytes

4.22

2.62

2.1

2.4

33.13

30.90

—

(3021589) Normoblasts [#/volume] in Blood

473

1.83

2.49

26.5

14.0

0.00

e9/l

0.64

384

(3000093) Morphology [Interpretation] in Blood Narrative

5.22

2.43

1.2

1.5

—

(3035933) Granulocytes/Leukocytes in Blood

3.83

2.41

5.1

1.7

57.38

61.11

—

(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay

3.83

2.41

2.6

1.4

—

(21494434) Karyotype in Bone marrow

6.48

2.39

1.0

—

(3014148) Varicella zoster virus Ab [Titer] in Serum

6.48

2.39

1.2

1.1

—

(3023601) Vancomycin resistant enterococcus [Presence] in Specimen by Organism specific culture

6.48

2.39

2.2

1.6

—

(3012544) pH of Venous blood

122

2.12

2.38

8.8

3.9

7.40

7.39

0.39

(3015377) Calcium [Moles/volume] in Serum or Plasma

411

1.80

2.37

4.3

3.6

2.32

2.36

mmol/l

0.97

368

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

3.04

2.27

1.1

1.4

—

(3021440) Promyelocytes/Leukocytes in Blood

2.21

2.27

2.3

3.9

0.00

0.08

—

(3019050) Tissue transglutaminase IgA Ab [Units/volume] in Serum

237

1.84

2.25

1.6

1.2

1.76

1.35

u/ml

0.15

(21493690) Lymphocyte T-cell and B-cell and Natural killer subsets panel - Blood

5.75

2.23

1.2

2.6

—

(3012220) Varicella zoster virus IgM Ab [Presence] in Serum by Immunoassay

5.75

2.23

1.2

—

(3026493) Urate [Moles/volume] in Serum or Plasma

291

1.78

2.17

3.9

2.8

361.97

340.34

umol/l

0.51

248

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

2.40

2.11

2.2

2.1

—

(3007853) Bacteria identified in Skin by Aerobe culture

128

2.01

2.10

1.5

1.7

—

(3019309) Folate [Moles/volume] in Red Blood Cells

217

1.82

2.07

2.3

1.7

1191.62

1213.10

nmol/l

0.05

160

(3037467) Urinalysis macro (dipstick) panel - Urine

696

1.85

2.04

6.6

5.0

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

463

1.70

2.01

4.8

4.3

63.12

36.77

ng/l

0.34

355

(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection

2.88

1.98

1.1

1.4

—

(3011960) Natriuretic peptide B [Mass/volume] in Serum or Plasma

2.20

1.97

4.0

3.1

258.75

237.64

ng/l

0.09

(3008757) Leukocyte morphology finding [Identifier] in Blood

4.70

1.96

2.0

4.5

—

(3013527) Hepatitis B virus core IgM Ab [Presence] in Serum

3.32

1.91

1.1

—

(3009595) Pneumocystis jirovecii DNA [Presence] in Specimen by NAA with probe detection

4.31

1.84

1.4

1.3

—

(3019060) Gas panel - Arterial blood

2.13

1.74

3.3

3.9

—

(40764126) Parainfluenza virus RNA [Presence] in Specimen by NAA with probe detection

3.97

1.73

1.0

1.3

—

(3045788) Cell count panel - Pleural fluid

3.97

1.73

1.4

1.1

—

(3045142) Bone marrow Pathology biopsy report

3.97

1.73

1.0

1.2

—

(3026008) Bacteria identified in Urine by Culture

362

1.63

1.72

3.9

3.5

—

(3015736) pH of Urine

439

1.61

1.68

4.3

3.8

6.45

6.24

0.72

240

(3002582) Erythrocytes [#/volume] in Urine

384

1.61

1.64

5.2

3.6

24.32

208.06

e6/l

0.57

299

(3037756) Immunofixation for Serum or Plasma

2.53

1.57

1.9

1.2

—

(3023024) Carbon dioxide [Partial pressure] in Capillary blood

2.08

1.57

6.6

4.3

4.47

4.98

kpa

1.43

(3021960) Folate [Moles/volume] in Serum or Plasma

369

1.59

1.56

2.1

1.7

16.98

20.63

nmol/l

0.95

295

(43055554) Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation

2.20

1.56

6.7

4.6

1.06

1.99

mmol/l

—

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

200

1.69

1.54

4.2

3.1

0.88

1.01

e6/l

0.12

105

(3030467) Casts [#/volume] in Urine by Automated count

333

1.59

1.54

5.8

3.4

0.55

0.45

e6/l

0.16

250

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

184

1.70

1.51

4.2

3.3

1.83

3.15

e6/l

0.50

(3000494) Fungus identified in Specimen by Culture

135

1.79

1.50

2.0

1.3

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

127

1.81

1.50

5.9

4.2

—

(3003327) Ova and parasites identified in Stool by Light microscopy

2.60

1.48

1.3

1.6

—

(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence

3.22

1.45

1.0

1.1

—

(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood

2.07

1.45

3.2

2.3

1.12

1.31

0.39

(3029937) Albumin [Presence] in Urine by Test strip

330

1.55

1.40

5.4

4.5

0.00

0.02

estimate

0.50

123

(3012516) Albumin [Mass/volume] in Urine

349

1.54

1.38

4.0

3.4

46.08

38.64

mg/l

0.18

223

(3012110) Lysozyme [Mass/volume] in Serum or Plasma

2.70

1.38

3.2

2.3

20.35

13.83

mg/l

—

(3018095) Leukocytes [#/volume] in Urine

415

1.53

1.38

6.3

4.6

13.07

105.42

e6/l

2.08

306

(40761536) Microorganisms panel - Urine sediment

1.89

1.38

7.4

4.4

—

(1761868) Lipid panel - Serum or Plasma

326

0.59

1.36

4.2

3.8

—

(3023419) Bacteria identified in Sputum by Culture

2.86

1.30

1.6

1.9

—

(3016293) Bicarbonate [Moles/volume] in Serum or Plasma

1.84

1.29

21.7

6.4

22.98

24.59

mmol/l

0.93

(3036086) Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay

2.48

1.26

1.7

1.3

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

395

1.48

1.21

6.1

3.5

—

(3019832) Treponema pallidum Ab [Presence] in Serum

2.13

1.18

2.5

1.4

—

(3045414) Leukocytes [Presence] in Urine

1.78

1.18

4.3

2.2

—

0.00

estimate

—

(4035726) Immunohistochemistry procedure

104

1.75

1.17

1.8

1.4

—

(3003694) ABO and Rh group [Type] in Blood

268

1.51

1.15

2.0

1.4

—

(3025941) Bacteria identified in Stool by Culture

2.06

1.15

1.4

1.3

—

(40760892) CBC W Ordered Manual Differential panel - Blood

224

1.53

1.14

7.5

5.0

—

(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection

2.09

1.08

4.0

2.2

—

(3009508) Creatinine [Moles/volume] in Urine

356

1.44

1.05

4.0

3.4

6.92

7.32

mmol/l

0.27

293

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

505

1.41

0.98

2.5

2.2

91.81

97.02

pmol/l

0.33

230

(3020059) Calcium [Moles/volume] corrected for albumin in Serum or Plasma

252

1.44

0.92

2.1

3.2

2.51

2.47

mmol/l

0.62

226

(3035350) Ketones [Presence] in Urine by Test strip

569

1.39

0.92

5.9

4.4

0.00

estimate

-0.00

130

(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection

1.93

0.89

1.4

1.2

—

(3022313) Gas panel - Capillary blood

1.88

0.88

8.9

5.3

—

(4024509) Urine culture

1.83

0.87

2.3

1.9

—

(3021601) Nitrite [Presence] in Urine by Test strip

564

1.37

0.84

5.8

4.4

0.00

estimate

-0.00

124

(37019628) Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection

1.92

0.83

3.7

1.6

—

(3009261) Glucose [Presence] in Urine by Test strip

576

1.36

0.81

6.2

4.4

0.00

estimate

-0.00

115

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

0.80

0.0

3.6

—

46.73

—

(3008364) Apolipoprotein A-I [Mass/volume] in Serum or Plasma

0.00

0.79

0.0

1.3

—

1.63

—

(3011831) Apolipoprotein B/Apolipoprotein A-I [Percentile]

0.00

0.78

0.0

1.3

—

0.53

—

(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection

1.81

0.77

1.5

1.9

—

(3043109) Cytology report of Tissue fine needle aspirate Cyto stain

2.23

0.77

1.0

1.3

—

(3022145) Colonoscopy Study observation

126

1.51

0.76

1.6

1.3

—

(3012477) Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection

2.13

0.75

1.0

1.3

—

(3037121) Protein [Mass/volume] in Urine

1.90

0.75

3.1

3.0

241.86

150.92

mg/l

—

(3015235) Bicarbonate [Moles/volume] in Capillary blood

1.80

0.73

4.3

2.4

21.73

24.24

mmol/l

—

(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection

1.97

0.71

1.0

1.3

—

(3020682) Albumin/Creatinine [Ratio] in Urine

359

1.32

0.68

5.5

4.2

7.81

6.77

mg/mmol

0.15

214

(3014791) Apolipoprotein B [Mass/volume] in Serum or Plasma

1.82

0.67

3.0

1.4

0.68

0.86

g/l

—

(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection

1.70

0.62

1.0

1.3

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

1.52

0.59

1.1

1.4

—

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

1.70

0.57

1.5

2.1

—

(3028626) Oxygen [Partial pressure] in Capillary blood

1.70

0.57

11.5

2.4

9.42

8.18

kpa

—

(40761511) CBC panel - Blood by Automated count

965

0.73

0.53

44.1

17.1

—

(3024889) Methemoglobin/Hemoglobin.total in Venous blood

1.54

0.51

4.3

2.3

0.76

0.63

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

499

1.25

0.50

2.9

2.7

—

(3002385) Erythrocyte [DistWidth] in Red Blood Cells

774

1.29

0.50

60.3

24.5

15.27

13.87

7.69

767

(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma

249

1.28

0.49

2.5

2.0

427.08

474.95

pmol/l

0.61

203

(3002256) Pathology report gross observation

158

1.32

0.46

1.5

1.2

—

(3020891) Body temperature

1.46

0.44

6.2

4.4

36.94

36.89

°c

—

(40758310) Human epididymis protein 4 [Moles/volume] in Serum or Plasma

1.59

0.43

1.8

1.3

221.60

89.79

pmol/l

—

(40764999) Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M

929

1.35

0.42

41.2

19.4

71.90

75.15

ml/min/173m2

0.80

876

(3048821) Cortisol [Moles/volume] in Serum or Plasma --post 1 mg dexamethasone PO overnight

0.00

0.41

0.0

1.1

—

(3016879) Cocaine [Presence] in Urine

0.00

0.41

0.0

1.2

—

(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.41

0.0

4.8

—

86.10

—

(3010421) pH of Blood

1.38

0.35

8.7

3.7

7.41

7.42

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

128

1.29

0.34

1.6

—

(3027238) Thyroperoxidase Ab [Units/volume] in Serum or Plasma

1.29

0.30

1.1

1.2

—

154.75

—

(3018251) Fasting glucose [Moles/volume] in Serum or Plasma

942

0.81

0.30

6.1

5.6

6.28

6.01

mmol/l

0.93

850

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

124

1.24

0.25

1.1

1.3

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

125

0.78

0.24

12.8

6.8

—

(3049717) Cytology report of Urine Cyto stain

1.33

0.23

2.6

—

(4146454) Self-monitoring of blood glucose

0.00

0.21

0.0

3.3

—

(3028707) Methadone [Presence] in Urine by Screen method

0.00

0.21

0.0

1.3

—

(21494670) JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method

0.00

0.21

0.0

1.0

—

(3038177) Helicobacter pylori Ab [Presence] in Serum

0.00

0.21

0.0

1.3

—

(3044242) Glucose [Moles/volume] in Arterial blood

0.00

0.21

0.0

1.8

—

8.89

—

(40768795) Lymph node Pathology biopsy report

0.00

0.21

0.0

1.1

—

(36032269) Testosterone Free [Moles/volume] in Serum or Plasma by calculation

0.00

0.21

0.0

1.7

—

219.00

—

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

0.21

0.0

1.5

—

(3005570) Glucose [Moles/volume] in Urine

0.00

0.21

0.0

3.1

—

(3009041) Cardiolipin IgG Ab [Units/volume] in Serum by Immunoassay

0.00

0.21

0.0

1.0

—

3.00

—

(1617658) Protocol used for examination of sentinel lymph nodes

0.00

0.21

0.0

1.1

—

(1001926) Buprenorphine [Presence] in Urine by Screen method

0.00

0.20

0.0

1.2

—

(3016251) Hemoglobin.gastrointestinal [Presence] in Stool

1.19

0.20

1.5

2.7

—

(40758558) Short blood count panel - Blood

333

1.12

0.17

9.6

6.7

—

(3000492) Spirometry study

1.22

0.16

1.9

1.6

—

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

213

0.87

0.16

3.7

5.2

29.06

22.95

—

115

(36660697) Celiac disease serology panel - Serum

0.78

0.16

1.0

1.1

—

(3004410) Hemoglobin A1c/Hemoglobin.total in Blood

931

0.87

0.15

8.7

7.1

41.40

40.14

mmol/mol

0.45

862

(3019150) Specific gravity of Urine by Refractometry

250

1.11

0.12

6.7

4.3

1.02

kg/l

0.23

165

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

431

1.07

0.10

5.7

4.4

0.00

0.03

estimate

0.50

109

(3041096) Erythrocytes [Presence] in Urine by Automated

322

1.08

0.10

4.9

4.1

0.00

estimate

-0.00

105

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

1.12

0.09

1.8

1.7

—

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

0.80

0.08

1.8

1.6

—

(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma

961

0.92

0.05

6.3

6.5

2.27

2.62

mmol/l

3.77

870

(3009201) Thyrotropin [Units/volume] in Serum or Plasma

909

1.07

0.05

5.5

5.7

2.28

1.94

mu/l

0.56

816

(3025839) Triglyceride [Moles/volume] in Serum or Plasma

428

1.05

0.04

1.9

2.0

1.39

1.27

mmol/l

0.47

349

(3008486) Thyroxine (T4) free [Moles/volume] in Serum or Plasma

749

1.00

0.00

4.8

4.6

15.19

15.01

pmol/l

0.21

669

(40768804) Tissue Pathology biopsy report

431

1.00

0.00

2.7

2.2

—

(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting

895

1.03

0.00

5.0

4.7

1.28

1.24

mmol/l

0.25

796

(3019900) Cholesterol [Moles/volume] in Serum or Plasma

941

0.99

0.00

5.8

5.6

4.13

4.57

mmol/l

3.66

851

(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma

941

0.99

0.00

5.6

5.5

1.39

1.51

mmol/l

1.79

846

(3013139) Helicobacter pylori Ag [Presence] in Stool

0.92

-0.00

1.2

1.4

—

(44813793) Dust mix specific IgE antibody measurement

0.00

-0.00

0.0

1.0

—

(40761535) Cells panel - Urine sediment

0.88

-0.00

5.0

2.8

—

(40758895) Direct antiglobulin test.complement C3d specific reagent [Presence] on Red Blood Cells

0.00

-0.00

0.0

2.7

—

(3044936) Clostridioides difficile toxin A+B [Presence] in Stool by Immunoassay

0.00

-0.00

0.0

1.0

—

(3000108) Respiratory syncytial virus B RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

2.0

—

(3037692) Legionella sp identified in Specimen by Organism specific culture

0.00

-0.00

0.0

1.0

—

(4010399) Spirometry for bronchospasm with prolonged evaluation after bronchodilator

0.96

-0.00

1.9

1.4

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

0.98

-0.00

2.2

1.3

—

(3043238) Trisomy 21 risk [Likelihood] in Fetus

0.00

-0.00

0.0

1.5

—

(40758897) Direct antiglobulin test.IgG specific reagent [Presence] on Red Blood Cells

0.00

-0.00

0.0

2.7

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

0.98

-0.00

1.8

1.4

—

(3049714) Procollagen type I.N-terminal propeptide [Mass/volume] in Serum

0.00

-0.00

0.0

1.8

—

71.67

—

(3025018) Bordetella pertussis Ab [Titer] in Serum

0.00

-0.00

0.0

1.1

—

(3006262) Parainfluenza virus 3 RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.8

—

(3014326) Insulin-like growth factor-I [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

2.6

—

22.80

—

(44816752) ERBB2 gene copy number/nucleus in Tissue by FISH

0.00

-0.00

0.0

1.0

—

(3030862) Granulocytes [#/volume] in Cerebral spinal fluid

0.00

-0.00

0.0

1.4

—

(3053028) Streptococcus sp identified in Specimen by Organism specific culture

0.00

-0.00

0.0

1.0

—

(3026470) Cobalt [Mass/volume] in Blood

0.00

-0.00

0.0

2.6

—

4.34

—

(3005156) Respiratory syncytial virus A RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

2.0

—

(3038297) Parainfluenza virus 4 RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.8

—

(3016436) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma

0.00

-0.00

0.0

6.8

—

200.40

—

(3012158) Parainfluenza virus 2 RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.8

—

(3030429) Borrelia sp DNA [Identifier] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection

0.00

-0.00

0.0

1.2

—

(4268621) Lupus anticoagulant assay

0.00

-0.00

0.0

1.8

—

(3046896) Herpes virus 6 DNA [Presence] in Cerebral spinal fluid by NAA with probe detection

0.00

-0.00

0.0

1.2

—

(43055089) Myosin Ab [Presence] in Serum or Plasma by Immunoblot

0.00

-0.00

0.0

1.3

—

(3019420) Tryptase [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

1.3

—

8.45

—

(3000855) Microscopic observation [Identifier] in Vaginal fluid by Gram stain

0.00

-0.00

0.0

1.5

—

(3025634) Parainfluenza virus 1 RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.8

—

(21493195) Respiratory pathogens DNA and RNA tested for in Respiratory system specimen by NAA with probe detection

0.00

-0.00

0.0

1.8

—

(3033306) Mononuclear cells/Leukocytes in Cerebral spinal fluid

0.00

-0.00

0.0

1.3

—

(3000285) Sodium [Moles/volume] in Blood

0.00

-0.00

0.0

1.0

—

140.20

—

(3002148) Methylenedioxymethamphetamine [Presence] in Urine by Screen method

0.00

-0.00

0.0

1.0

—

(3047352) Trisomy 18 risk [Likelihood] in Fetus

0.00

-0.00

0.0

1.0

—

(3012447) Hantavirus puumala IgG Ab [Titer] in Serum

0.00

-0.00

0.0

1.1

—

(3049207) Fetal Trisomy 21 risk [Likelihood] Based on maternal age

0.00

-0.00

0.0

1.0

—

Mortality – FinRegistry

↥

Association

Association between endpoint CHIRBIL_NAS and mortality.

Females

Parameter	HR [95% CI]	p-value
CHIRBIL_NAS	4.689 [3.16, 6.97]	< 0.001
Birth year	0.993 [0.98, 1.0]	0.134

During the follow-up period (1.1.1998 — 31.12.2019), 149 out of 349 females with CHIRBIL_NAS died.

Males

Parameter	HR [95% CI]	p-value
CHIRBIL_NAS	5.621 [3.23, 9.79]	< 0.001
Birth year	0.988 [0.98, 1.0]	0.01

During the follow-up period (1.1.1998 — 31.12.2019), 120 out of 207 males with CHIRBIL_NAS died.

Mortality risk

Mortality risk for people of age

years, who have CHIRBIL_NAS.

N-year risk	Females	Males
1	0.314%	1.206%
5	2.226%	6.182%
10	6.182%	15.232%
15	11.143%	27.835%
20	19.285%	44.691%

Relationships between endpoints

↥

Index endpoint: CHIRBIL_NAS – Biliary cirrhosis, NAS

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Biliary cirrhosis, NAS

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

Matched cohort

TimeCodeWAS

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints